VA	ALIANT LABORATORIES LIMITED				ANNEXU (Rs In N
RE	STATED SUMMARY STATEMENT OF ASSETS AND LIABIL THE Particulars	Notes	March 31, 2023	March 31, 2022**	March 31, 2021
. AS	SSETS				
	on-Current assets				
	Property, plant & equipment	4	291.41	217.73	19
	Capital Work-in-Progress	4	0.46	14.45	
	Right to Use-Assets	5	8.28	4.54	
) Goodwill				
	Other Intangible Assets		_	_	
	Financial Assets				
	(i) Investment in Subsidiaries	6A	0.10	_	
	(ii) Other Financial Assets	7A	7.02	6.10	
- 1	Other non-current assets	8	0.68	7.33	
	otal Non-Current assets		307.95	250.14	2
	arrent assets	-+-+	007.50		
	Inventories	9	130.42	158.04	
	Financial Assets				
(0)	(i) Investments	6B	340.19	4.02	
1	(ii) Trade Receivables	10	885.68	1,107.69	42
		11	3.76	1.31	
	(iii) Cash and Cash Equivalents (iv) Bank Balances Other than Cash & Cash Equivalents	12	0.80	200.00	15
	· ·	13	324.03	0.01	
	(v) Loans	7B	7.22	7.30	
	(vi) Other Financial Assets				18
	Other Current assets	14	108.57	73.61	10
	Current Tax Assets (Net)	15	18.95	15.99 1.567.98	01
	tal Current assets		1,819.63 2,127.58	1,818.12	1,06
-	otal Assets OUITY AND LIABILITIES		4,141,30	1,010.12	1,00
	QUITY	16	325.60	162.80	10
	Equity Share Capital	17	679.30	551.80	78
managed when the	Other Equity	1/	1,004.90	714.60	88
	abilities		1,009.70	712.00	- 00
	on-Current liabilities	1	£ .		
(a)) Financial Liabilities				
	(i) Borrowings	18A	594.00	594.00	
- 1	(ii) Lease Liabilities	19A	6.42	2.67	
	(iii) Other financial liabilities	20	9.61	9.61	
(b)	Provisions	21A	0.78		
	Deferred Tax Liabilities (net)	22	6.66	2.96	
	tal non-current liabilities		617.48	609.25	1
Cu	rrent Liabilities				
(a)	Financial Liabilities				
	(i) Borrowings	18B	-	12.81	
((ii) Lease Liabilities	19B	1.75	1.78	
((iii) Trade Payables	23			
	A) Total Outstanding Dues of Micro enterprises and				
	and small enterprises		0.06	0.18	
	B) Total Outstanding dues of Creditors other than				
	Micro enterprises and small enterprises		472.90	464.19	12
1	(iv) Other Financial Liabilities	24	20.18	13.07	
(b)	Other Current liabilities	25	9.11	0.68	
	Provisions	21B	1.18	1.56	
	Current Tax Liabilities (Net)	26	-	••	2
	otal current liabilities		505.19	494.27	15
- m	otal Equity and Liabilities		2,127.58	1,818.12	1,06

** Restated financials includes period of Partnership Firm from 01/04/2020 to 15/08/2021

Significant accounting policies and Key accounting estimates and judgements.

The above statement of Balance Sheet should be read in conjunction with the accompanying notes.

Previous Year's figures are regrouped / rearranged wherever required.

As per our report of even date attached

For Raman S Shah & Co Chartered Accountants (Firm Regn No. 111919W)

Raman S Shah

Proprietor M. No.033272 Place : Mumbai Date - May 23rd, 2023 UDIN -



For and on behalf of the Board of Directors Valiant Laboratories Limited

Mr. Santosh S Vora DIN - 07633923 Managing Director

Mr. Paresh S Shah Director & CFO DIN - 08291953

Ms. Saloni Mehta
Company Saloni Company Secretary ICSI M. No.- A65706

VALIANT LABORATORIES LIMITED SS

(14.39)

22.29

0.24

16.18

79.33

1797.32

302.08

77.25

(2.60)

74.65

227.42

(1.45)

(0.05)

(1.50)

225,92

7.87

7.87

Sr No.	Particulars
I	Revenue from operations Other Income
III	Total Income
IV	EXPENDITURE Cost of Materials Consumed Purchase of stock in trade
	Changes in Inventories of Finished Goods & Work-in-Progress Employee Benefits Expense Finance Costs
	Depreciation and Amortization Other Expenses
IV	Total Expenditure
V	Profit Before Tax
VI	Tax Expenses Current Tax Deferred Tax
VI	Total Tax Expense
VII	Profit for the year
VIII	Other Comprehensive Income (i) Items that will not be reclassified to profit or loss in subsequent year
	Re-measurement of the net defined benefit plan Fair value changes of various Financial intruments (ii) Income tax relating to items that will not be reclassified t

Re-measurement of the net defined benefit plan

Fair value changes of various Financial intruments Total other comprehensive income for the year, net of tax

Total comprehensive income for the year (VII + VIII)

Previous Year's figures are regrouped / rearranged wherever required.

(Total of profit and other comprehensive income for the year) Earnings per equity share of Rs. 10/- each (PY: Rs. 10/- each)

profit & loss

(1) Basic

(2) Diluted

VIII

Proprietor

UDIN -

IX

		For the year ended 31st March, 2023
7	27	3339.10
	28	48.63
		3387.72
	29 30	2772.77 2.83
	31 32	(2.41) 46.13
- 1	33	2.54

15.63

168.87

3006.36

381.36

88.00

3.38

91.38

289.98

0.64

(0.32)

0.32

8.91

8.91

290,30

Notes

34

35

22

22

16th August 2021 to March 2022	1st April 2021 to 15th August 2021
2091.44	823.79
7.95	11.53
2099.40	835.32
1690.45	673.85
3.22	0.38

For the year ended 31st March, 2022**

31st March, 2022**

(5.34)

8.35

0.49

8.72

33.91

720.36

114.96

67.42 0.00

67.42

47.54

0.00

47,54

1.68

1.68

Valiant Laboratories Limited

S.S. voia

2915.23 19.49 2934.72 2364.30 3.60 (19.74)

For the year ended

30.64 0.73 24.90

113.24 2517.68 417.04

144.68 (2.60)142.08 274.96

(1.45)

(0.05)

(1.50)

273.46

ANNEXURE II

(Rs In Mn. Except EPS)

For the year ended

31st March, 2021**

1823.69

1837.81

1208.73

0.11

(1.27)

27.08

17.84

26.07

89.02

1367.59

470.23

164.60

(0.30)

164.30

305.93

0.00

305.93

10.83

10.83

14.12

Mr. Paresh S Shah

9.52 9.52 For and on behalf of the Board of Directors Director & CFO DIN - 08291953

22 36.1 ** Restated financials includes period of Partnership Firm from 01/04/2020 to 15/08/2021 The above statement of Profit and Loss should be read in conjunction with the accompanying notes.

As per our report of even date attached For Raman S Shah & Co Chartered Accountants (Firm Regn No. 111919W)

Raman S Shah M. No.033272 Place: Mumbai Date - May 23rd, 2023

Mr. Santosh S Vora Managing Director DIN - 07633923

Ms. Saloni Mehta Company Secretary ICSI M. No.- A65706

(Rs In Mn.)

470.23

26.07

17.84

514.14

(207.01)

(22.04)

(64.99)

(0.08)

14.43

(1.85)

22.11

255.69

(164.60)

91.09

(16.69)

(150.00)

(17.84)

132.14

114.30

38.69

0.68

39.37

38.69

0.69

39.37

March 31, 2021**

0.00

0.00 (166.69)

0.98

FS	TI	MI	TE	D	

ES	LI	M	IT	ED	

CASH	FLOW	

ANNEXURE-III

VALIANT LABORATORI

RESTATED SUMMARY STATEMENT OF C

Gain/(Loss) on disposal of Property, Plant and Equipment (PPE)

Operating Profit /(Loss) before Working Capital Changes

PARTICULARS CASH FLOW FROM OPERATING ACTIVITIES;

Net Profit before tax and extra ordinary items

(Increase)/Decrease in Trade Receivables

(Increase)/Decrease Other Current Assets

(Increase)/Decrease Other non-Current Assets

Increase/(Decrease) in Other Current Liabilities

CASH FLOW FROM INVESTING ACTIVITIES:

CASH FLOW FROM FINANCING ACTIVITIES:

Purchase of property, plant & equipment (including capital advances)

Bank Balances not considered as Cash and Cash Equivalents

Net increase / (decrease) in Cash and Cash Equivalents (A+B+C)

** Restated financials includes period of Partnership Firm from 01/04/2020 to 15/08/2021

Acci

The above Cash Flow Statement has been prepared under "Indirect Method" set out in Ind AS 7 Statement of Cash Flow.

The accompanying notes are an integral part of the Ind AS financial statements. Previous Year's figures are regrouped / rearranged wherever required.

Cash and Cash Equivalents at the beginning of the year

Cash and Cash Equivalents at the end of the year

Total cash and cash equivalents at end of the year

(Increase)/Decrease in Inventories

Increase/(Decrease) in Trade Payable

Cash generated from operations

Net cash from operating activities

Sale of property, plant & equipment

Net Cash used in investing activities

Proceeds / (Repayments) of Borrowings

Proceeds / (Repayments) of share capital

Net Cash used in financing activities

Cash and cash equivalents comprise

Exp for issue of Share capital

Increase/(Decrease) in Lease Liabilities

Increase/(Decrease) in Financial Liabilities

Adjusted for:

Depreciation

Interest Paid

Adjusted for:

Income Tax Paid

Other Investment

Interest Paid

Particulars

Cash on hand

For Raman S Shah & Co

Chartered Accountants

Proprietor M. No.033272

UDIN -

Place : Mumbai

Date - May 23rd, 2023

(Firm Regn No. 111919W)

Balances with banks

Figures in brackets indicate cash outgo.

As per our report of even date attached

B.

March 31, 2021** March 31, 2023 March 31, 2022**

417.04 381.36

24.90

6.15

0.40

447.69

(682.72)

(97.31)

(17.39)

(0.15)

1.92

62.52

99.26

167.18

22.51

(68.76)

(50.00)

(4.02)

(6.15)

(0.31)

488.99

61.81

(38.06)

39.37

1.31

0.11

1.20

1.31

March 31, 2022**

(420.72)

(122.38)

0.40

(144.68)

353.35

15.63

2.54

399.53

222.01

(325.53)

27.61

2.01

68.39

3.72

8.43

(88.62)

317.56 (88.00)

229.56

(70.68)

199.20

(340.29)

(211.77)

(2.54)

(12.81)

(15.34)

2.45

1.31

3.76

3.21

0.55

3.76

For and on behalf of the Board of Directors

Mr. Paresh S Shah

Director & CFO

DIN - 08291953

Valiant Laboratories Limited

S.S. VO12 Mr. Santosh S Vora

Managing Director

DIN - 07633923

Ms. Saloni Mehta

Company Secretary

ICSI M. No.- A65706

March 31, 2023

VALIANT LABORATORIES LIMITED

Standalone Statement of Changes in Equity as restated

Particulars

Particulars

A. Equity Share Capital Current Reporting Period

Total

Ordinary Equity Shares

Previous Reporting Period

Ordinary Equity Shares

Bonus Share Issue

Issue of Shares - Right issue

Balance as at 31st March, 2021

Net profit for the year

Issuance of Bonus Shares

Proprietor M. No.033272 Place: Mumbai

UDIN -

Restasted balance as at 1st April 2021

Security premium during the year

Expenses incurred for issuance of Bonus Shares

Total 105.00 Changes in equity Particulare Balance as on April share capital during 1, 2020 the period Ordinary Equity Shares 105.00 Total 105.00 **B.** Other Equity Particulars Restasted balance as at 1st April 2020 Net profit for the year

Changes in accounting policies and prior periods errors Add / (Less): Transactions in Current Capital Accounts ** Add / (Less): Transfer to secueity premium from partner's capital Remeasurement Gain/(Loss) on defined benefit plan (net of tax)

Balance as on April

1. 2022

Balance as on April

1, 2021

162.80

162.80

105.00

Changes in equity

share capital due to

prior period errors

Changes in equity

share capital due to

prior period errors

Issuance of Bonus Shares Balance as at 31st March, 2022 Changes in accounting policies and prior periods errors Restasted balance as at 31st March, 2022 Net profit for the year

Add / (Less): Transactions in Current Capital Accounts **

Balance as at 31st March, 2023 1. The accompanying notes are an integral part of the Ind AS financial statements.

Remeasurement Gain/(Loss) on defined benefit plan (net of tax)

2. Previous Year's figures are regrouped / rearranged wherever required. 3. Retained Earnings include Remeasurement Loss (net of tax) on Defined Benefit Plans to the extent of Rs. 1.18 Mn. (P.Y. of Rs. 1.5 Mn)

Raman S Shah & Co

Chartered Accountants

(Firm Regn No. 111919W)

S.S. W19.

Mr. Santosh S Vora Managing Director

DIN - 07633923

For and on behalf of the Board of Directors Valiant Laboratories Limited

Mr. Paresh S Shah

Reststated Balance at

the current reporting

periods

Reststated Balance at

the current reporting

periods

Balance as on March

31, 2021

Security Reserve

162.80

162.80

105.00

105.00

105.00

105.00

340.99

(14.80)

326,19

326.19

(162.80)

163.39

Reserve and surplus

Changes in equity

share capital during

the period

Changes in equity

share capital during

the period

Changes in equity

share capital during

the period

Retained Farnings

281.24

305,93

193.65

780.82

780.82

274.96

(487.37)

(340.99)

(1.50)

(0.31)

225,61

225,61

289.98

515.91

0.32

162.80

43.00

14.80

57.80

(Rs. in Mn)

325.60

325.60

105.00

43.00

14.80

162.80

105.00

105.00

281 24

305.93

193.65

780.82

780.82

274.96

(487.37)

(340.99)

340.99

(1.50)

(0.31)

(14.80)

551.80

551.80

289.98

(162.80)

679.30

0.32

(Rs. in Mn) Total other equity

(Rs. in Mn)

Balance as on 31-03-

2023

Balance as on 31-03-

(Rs. in Mn)

Balance as on 31-03-

2021

Director & CFO DIN - 08291953

Date - May 23rd, 2023 Ms. Saloni Mehta Company Secretary ICSI M. No.- A65706

VALIANT LABORATORIES LIMITED

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND OTHER RELATED NOTES Corporate Information

The Company was formed by conversion of a partnership firm, under the provisions of Companies Act, 2013. The Firm was formed and registered as a partnership firm under the provisions of Indian Partnership Act, 1932, pursuant to a deed of partnership, as amended and supplemented from time to time. The Firm was converted to a Public limited Company on August 16, 2021 and the name of our Company was changed to "VALIANT LABORATORIES LIMITED ("VLL" or "The Company"). Consequently, a fresh certificate of incorporation was issued by the RoC on August 16, 2021. VALIANT LABORATORIES LIMITED ("VLL" or "The Company") is public limited entity incorporated in India. The registered office of the 104 UDYOG KSHETRA IST FLOOR MULUND GOREGAON LINK ROAD MULUND (W) MUMBAI MH 400080 INDIA bearing CIN No : orated in India. The registered office of the Company is located at

SUMMARY OF BASIS OF COMPLIANCE, BASIS OF PREPARATION AND PRESENTATION, AND CRITICAL ACCOUNTING ESTIMATES,

The company's financial statements have been prepared in accordance with the provisions of the Companies Act, 2013 and the Indian Accounting Standards ("Ind As") notified under the Companies (Indian Accounting Standards) Rules, 2015 issued by Ministry of Corporate Affairs in respect of Section 133 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules issued thereafter. In addition, the guidance notes/announcements issued by the Institute of Chartered Accountants of India (ICAI) are also applied except if compliance with other statutory promulgations require a different treatment.

The date of transition to Ind AS is April 1, 2019. The financial statements upto the year ended March 31, 2020 were prepared in accordance with the accounting standards notified under the Companies (Accounting Standards) Rules, 2006 ("I-GAAP") and other relevant provisions of the Act. The figures for the year ended March 31, 2020 have now been restated as per Ind AS to provide comparability

The financial statements have been prepared in accordance with Generally Accepted Accounting Principles in India (referred to as "IND AS") as prescribed under

These Financial statement are prepared under the historical cost convention on an accrual basis except for certain financial instrument, which are measured at fair

The classification of assets and liabilities of the company is done into current and non-current based on the operating cycle of the company. The Operating cycle of the business of the company is less than twelve months and therefore all current and non-current classification are done on the status of reliabity and expected settlement of the respective assets and liability within a period of twelve months from the reporting date as required by Schedule III to the companies Act 2013. Accounting policies have been consistently applied except whereas newly issued accounting standard is initially adopted or revision to an existing accounting standard required a change in the accounting policy hitherto in use.

The financial statements are presented in Indian rupees ('INR') and all valued are rounded to the nearest rupees in Million except otherwise indicated

The preparation of financial statements requires management judgements, estimates and assumptions that impacts the reported amounts of revenues, expenses assets and liabilities, and the accompanying notes thereon. Uncertainty about these assumptions and estimates could result in outcomes that might require a

The preparation of the financial statements in conformity with IND AS requires management to make estimates, judgments and assumptions. These estimates, judgments and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of circumstances surrounding the estimates. Changes in estimates are reflected in the financial statement in the period in which changes are made and if material, their effects are disclosed in the

The company's management has made the following judgement, which have the most significate effect on the amounts recognised in the separate financial

Tax expense comprises of current tax and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities, using the applicable tax rates. Deferred income tax reflect the current period timing differences between taxable income and accounting income and reversal of timing differences of earlier years/period. Deferred tax assets are recognised only to the extent that there is a reasonable certainty that sufficient future income will be available except that d tax assets, in case there are unabsorbed depreciation or losses, are recognised if there is virtual certainty that sufficient future taxable income will be

Deferred tax assets and liabilities are measured using the tax rates and tax law that have been enacted or substantively enacted by the Balance Sheet date. The company offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognised amounts and where it intends either to

The cost of the defined benefit gratuity plan and the present value of the gratuity obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long term nature, a defined benefit obligation highly sensitive to changes in

Discount rate: The said parameter is subject to change. In determining the appropriate discount rate (for plans operated in India), the management considers the interest rates of government bond in currencies which are consistent with post- employment benefit obligation. The underlying bonds are reviewed periodically for

Mortality rate: It is based on publicly available mortality tables. Those mortality tables tend to change at an interval in response to demographic changes

The company reviews the useful life of property, plant & equipment at the end of each reporting period. This reassessment may result in change in depreciation

HIMEA

A8000

quality. Those having excessive credit spreads are excluded from the analysis since that they do not represent high quality corporate bonds.

section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time.

The Company is engaged in manufacturing and dealing in Pharmaceuticals and specility chemicals.

The Company Valiant Laboratories Ltd. was converted from Partnership Firm. (Bharat Chemicals.) to Public Ltd. The Company has prepared the opening Balance Sheet as per Ind AS as of 1st April, 2019 (the transition date) by recognising all assets and liabilities whose recognition is required by Ind AS, not recognising items of assets or liabilities which are not permitted by Ind AS, by reclassifying items from previous GAAP to Ind AS as required under Ind AS, and applying Ind AS in

1124299MH2021PLC365904.

facts and circumstances that existed as of the transition date.

ASSUMPTIONS AND JUDGMENTS

Basis of Preparation of Financial Statements

notes to the financial statements.

available to realise the same.

Defined Benefit Plans (Gratuity Benefits)

Useful lives of property, plant and equipment

expense in future periods

Judgments

value, which are disclosed in the financial statement.

Significant accounting judgement, estimates, and assumption

statements, while formulating the company's accounting policies.

settle on a net basis, or to realise the asset and settle the liability simultaneously.

Prospective increase in salary and gratuity are based on expected future inflation rates

these assumptions. All assumptions are reviewed at each reporting date.

material adjustment to the carrying amount of assets and liabilities in future periods.

Basis of Compliance

General Principal

measurement of recognised assets and liabilities. However, this principle is subject to certain mandatory exceptions and certain optional exemptions availed by the Company as detailed below

The Company has determined the classification of debt instruments in terms of whether they meet the amortised cost criteria or the FVTOCI criteria based on the

Current and non-current classification

All assets and liabilities have been classified as current or non-current as per company's normal operating cycle and other criteria set out in the Division II of Schedule III to the Companies Act, 2013 Based on the nature of products and the time between acquisition of assets for processing and their realisation in cash and cash equivalents, the company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities. An asset is treated as current when : -It is expected to be realised or intended to be sold or consumed in normal operating cycle; It is held primarily for the purpose of trading It is expected to be realised within 12 months after the reporting period; or It is cash and cash equivalent unless restricted from being exchange or used to settle a liability for at least twelve months after the reporting period The company's classifies all other assets as Non-Current A Liability is treated as current when It is expected to be settled in normal operating cycle; It is held primarily for the purpose of trading It is due to be settled within twelve months after the reporting period; or There is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. The company's classifies all other assets as Non-Current Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

Property, plant and equipment are stated at cost net of tax /duty credit availed, less accumulated depreciation and accumulated impairment losses, if any. Cost Property, plant and equipment are stated at cost net of tax /duty credit availed, less accumulated depreciation and accumulated impairment losses, if any, cost comprises of purchase price inclusive of taxes, commissioning expenses, etc. up to the date the saset is ready for its intended use, when significant parts of property, plant and equipment are required to be replaced at intervals, the company dereconguizes the replace part, and recognizes the new part with its own associated useful life and it is depreciated accordingly. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance cost are recognised in the statement of profit and loss as

Incurred.

Long term lease arrangements of land are treated as property, plant and equipment, in case such arrangements result in transfer of control and the present value of the lease payments is likely to represent substantially all of the fair value of the land.

Capital Work in Progress represents expenditure incurred on capital assets that are under construction or are pending capitalisation and includes Project expenses pending allocation. Project expenses pending allocation are apportioned to the property, Plant and equipment of the project proportionately on capitalisation.

Depreciation on Fixed Assets is provided on Straight Line Method (SLM) method as per rates prescribed in Schedule II of the Companies Act, 2013, except in the respect of the following assets, where useful life of asset is different than those prescribed in Schedule II of the Act. Depreciation

Over its useful life as assessed

Over its useful life as assessed

Over the period of lease term

Over its useful life as assessed

Borrowing costs directly attributable to the acquisition, construction or production of an assets that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent

In determining the amount of borrowing costs eligible for capitalization during a period, any income earned on the temporary investment of those borrowings is

Raw Materials and packing materials are valued at Lower of Cost or market value, (Cost is net of taxes duty and wherever applicable). However materials an other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to

Borrowing cost on property, plant and equipment's are capitalised when the relevant recognition criteria specified in IND AS 23 Borrowing cost is met. Decommissioning costs, if any, on property, plant and equipment are estimate at their present value and capitalised as part of such assets.

For property, plant and equipment and intangibles an assessment is made at each reporting date to determine whether there is an indication that the carrying amount may not be recoverable or previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine

The Company estimates the net realisable value (NRV) of its inventories by taking into account estimated selling price, estimated cost of completion, estimated costs necessary to make the sale, obsolescence considering the past trend. Inventories are written down to NRV where such NRV is lower than their cost.

The recognition and measurement of other provisions is based on the assessment of the probability of an outflow of resources, and on past experience and circumstance known at the closing date. The actual outflow of resources at a future date may therefore, vary from the amount included in other provisions.

An item of property, plant and equipment and any significate part initially recognised is derecognised upon disposal or when no future economic benefits are expected with the carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repair and maintenance are charge wi to profit or loss during the reporting period in which they are incurred. vii The residual value and useful lives of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate. The Property, plant and equipment existing on the date of transition are accounted on deemed cost basis by applying para D7AA in accordance with the exemption provided in IND A5 101 "First-time Adoption of Indian Accounting Standards" at previous GAAP carrying value (Deemded Cost). viii

Items of inventories are valued lower of cost or estimated net realisable value as given below.

be sold at or above cost. Costs are determined on Weighted Average method

III Depreciation methods, estimated useful lives and residual value

Factory Building (Useful 30 Years)

Vehicle (Useful life 10 years)

Leasehold Land

IV Borrowing costs

Inventories

Plant & Machinery (Useful life 19 years)

regarded as an adjustment to the borrowing costs.

deducted from the borrowing costs incurred.

Raw Materials and Packing Materials:

Impairment of property, plant and equipment

Recognition and measurement of other Provisions

Summary of Significant accounting policies

II Property, plant and equipment (PPE)

incurred

Inventories

the asset's recoverable amount since the last impairment loss was recognised.

Work in process are valued at the lower of cost and net realizable value. The cost is computed on weighted average method. Finished Goods and Semi finished goods :-Finished Goods and Semi finished goods are valued at lower of cost and net realised value. The cost is computed on weighted average method and includes cost of materials, cost of conversion and other cost incurred in acquiring the inventory and bringing them to their present location and condition. Taxes is considered as cost for finished goods, whenever applicable. Stores and Spares: Stores and spare parts are valued at lower of purchase Costs are determined on Weighted Average method and net realisable value. Traded Goods: Traded Goods are valued at lower of purchase cost and net realisable value. VI Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and demand deposit with banks, which are short term, highly liquid investment, that are readily convertible into known amounts of cash and which are subject to insignificant risk of change in value.

SHAL



VII Equity investment All equity investment in scope of INDAS 109 are measured at fair value. Equity instruments, which are held for trading, are classified as at FVTPL. For all other equity instruments, the company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company makes such election on an instrument-by instrument basis, the classification is made on initial recognition and is irrevocable, if the company decides to classify an equity instrument as at FVTOCI, then all fair value change on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to statement of profit and loss, even on sale of investment. However, The company may transfer the cumulative gain or loss within equity. Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit & loss.

VIII Foreign Currency Translation: The company's financial statements are presented in INR, which is also the company's functional currency. Foreign currency transactions are recorded on initial recognition in the functional currency, using the exchange rate at the date of the transaction. At each balance sheet date, foreign currency monetary items are reported using the closing exchange rate. Exchange differences that arise on settlement of monetary items or on reporting at each balance sheet date of the Company's monetary items at the closing rate are recognized as income or expenses in the period in which they arise. IX Provisions, Contingent Liabilities and Contingent Assets

Provisions

Contingent liabilities

cannot be recognised because it cannot be measured reliably.

Contingent Assets A contingent assets is not recognised unless it become virtually certain that an inflow of economic benefit will arise. When an inflow of economic benefits is

In the principal market for the asset or liability, or

market participants act in their economic best interest.

market participants act in their economic best interest."

Contingent liabilities are disclosed in respect of possible obligations that arise from past event, whose existence would be confirmed by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the Company. A contingent liability also arises, in rare cases, where a liability

The Company recognizes a provision when: it has a present legal or constructive obligation as a result of past events, it is likely that an outflow of resources will be required to settle the obligation; and the amount has been reliably estimated. Provisions are not recognized for future operating losses. Provisions are reviewed at each balance sheet and adjusted to reflect the current best estimates.

presumption that the transaction to sell the asset or transfer the liability takes place either: -

use or by selling it to another market participant that would use the asset in its highest and best use.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that

Ind AS 115 is effective from 1st April 2018 and it replaces Ind AS 18. It applies, with limited exceptions, to all revenue arising from contracts with its customers. Ind AS 115 establishes a five-step model to account for revenue arising from contracts with customers and requires that revenue be recognized at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. Ind AS 115 requires entities to exercise judgement, taking into consideration all of the relevant facts and circumstances when applying each step of the model to contracts with their customers. It also specifies the accounting for the incremental costs of obtaining a contract and the costs directly related to fulfilling a contract. Revenue is recognised upon transfer of control of promised products or services to customers in an amount that reflects the consideration which the company

probable, contingent assets are disclosed in the financial statements. Contingent liabilities and contingent assets are reviewed at each balance sheet date

A provision for onerous contracts is measured at the present value of the lower expected costs of terminating the contract and the expected cost of continuing with the contract. Before a provision is established, the Company recognizes impairment on the assets with the contract.

The company measures financial instruments, such as, derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the

In the absence of a principal market, in the most advantageous market for the asset or liability The principal or the most advantageous market must be accessible by the Company.

follows, based on the lowest level input that is significate to the fair value measurement as a whole :-Level 1 - Quoted (unadjusted) market prices in active markets for identical assets or liabilities Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly and indirectly observable Level 3 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly and indirectly unobservable.

For assets and liabilities that are recognized in the balance sheet on a recurring basis, the Company determines whether transfers have occurred between levels in

the hierarchy by re assessing categorization (based on the lowest level input that is significate to the fair value measurement as a whole) at the end of each reporting For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

Eligible export incentives are recognised in the year in which the conditions precedent are met and there is no significant uncertainty about the collectability. In respect of incentives attributable to the export of goods, the Company following the accounting principle of matching revenue with the cost has recognised export incentive receivable when all conditions precedent to the eligibility of benefits have been satisfied and when it is reasonably certain of deriving the benefit, since

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured, regardless of when the payment is being made.

period.

XII Revenue Recognition Revenue from Operations:

> Revenue is recognized at point in time when the performance obligation with respect to Sale of goods or rendering of services to the Customer which is the point in time when the customer receives the goods and services. Revenue from related parties is recognized based on transaction price which is at arm's length Revenue is measured at the fair value of the consideration received or receivable, after the deduction of any trade discounts, volume rebates , sales return on transfer of control in respect of ownership to the buyer which is generally on dispatch of goods and any other taxes or duties collected on behalf of the Government

expects to receive in exchange for those products or services

which are levied on sales such as Goods and Services Tax (GST). Discounts given include rebates, price reductions and other incentive given to customers. No element of financing is deemed present as the sales are made with a payment term which is consistent with market practice.

Revenue from services is recognised when all relevant activities are completed and the right to receive income is established. This is applicable in case of Job Work services given by the Company to the Customers. The Company disaggregates revenue from sale of goods or rendering of services with customers by product classification, geographical region and customer

category. Use of significate judgements in revenue recognition

The company assesses the service promised in a contract and identifies distinct performance obligation in the contract. Identification of distinct preformation obligation involves judgement to determine the deliverables and the ability of the customer to benefit independently from such deliverables.

Judgement is also required to determine the transaction price for the contract. The transaction price could be either a fixed amount of customer consideration or

variable consideration with elements such as volume discounts, service level credits, price concessions. The transaction price is also adjusted for the effects of the

time value of money if the contract includes a significant financial component.

The company used judgement to determine an appropriate standalone selling price for a performance obligation. The Company allocates the transaction price to each performance obligation on the basis of the relative standalone selling price of each distinct service promised in the contract. Other Operating Income / Other Income

these schemes are meant for neutralisation of duties and taxes on inputs pursuant to exports, the same are grouped under material costs. The other export incentives that do not arise out of neutralisation of duties and taxes are disclosed under other operating revenue



Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principle outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

- Revenue in respect of Insurance /other claims, commission etc. are recognised only when it is reasonably certain that the ultimate collection will be made.
- Dividend income is recognised when the right to receive the same is established
- Current investments are marked to market at the end of the relevant period and the resultant gains or losses are recognised in the Income statement.
 - For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments
- Insurance Claim are accounted when the right to receive is established and the claim is admitted by the surveyor

XIII Taxes

Tax expenses comprise Current Tax and Deferred Tax.:

Current Tax

Tax on income for the current period is determined on the basis of estimated taxable income and tax credits computed in accordance with the provisions of the relevant tax laws and based on the expected outcome of assessments/ appeals.

Current income tax relating to item recognized directly in equity is recognized in equity and not in the statement of profit and loss. Management periodically

evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

where appropriate.

The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax is provided using the balance sheet approach on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amount in the standalone financial statement for financial reporting purposes at the reporting date.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting and are recognized to the extent that it has become probable that future taxable profits will the deferred tax assets to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or liability settled, based on the tax rates (tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

The break-up of major components of deferred tax assets and liabilities as at balance sheet date has been arrived at after setting off deferred tax assets and liabilities where the Company have a legally enforceable right to set-off assets against liabilities and where such assets and liabilities relate to taxes on income levied by the same governing taxation laws. For items recognised in OCI or equity, deferred / Current tax is also recognised in OCI or Equity.

At the inception of each lease, the lease arrangement is classified as either a finance lease or an operating lease, based on the substance of the lease

operating lease Lease in which a significant portion of the risk and reward of ownership are not transferred to the company as lessee are classified as operating lease.

Payments made under operating leases (net of any incentives received from the lessor) are charge to statement of profit and loss on a straight line basis over the period of the lease unless the payments are structured to increase in line with expected general inflation to compensate for the lessor's expected general inflation to compensate for the lessor's expected inflationary cost increase.

Assets leased by the Company in its capacity as lessee where substantially all the risks and rewards of ownership vest in the company are classified as finance lease

A Finance lease is recognized as an asset and a liability at the commencement of the lease, at the lower of the fair value of the asset and the present value of the minimum lease payments. Minimum lease payments made under finance lease are apportioned between the finance expense and the reduction of the outstanding liability. The Finance expenses is allocated toeach period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Leasehold lands are amortized over the period of lease. Buildings constructed on leasehold land are depreciated based on the useful life specified in Schedule II to

the companies Act, 2013, where the lease period of land is beyond the life of the building. In other cases, buildings constructed on leasehold lands are amortized over the primary lease period of the lands.

Lease income from operating leases where the Company is a lessor is recognised in income on a straight-line basis over the lease term unless the receipts are structured to increase in line with expected general inflation to compensate for the expected inflationary cost increase. The respective leased assets are included in the balance sheet based on their nature. The Company did not need to make any adjustments to the accounting for assets held as lessor as a result of adopting the new leasing standard.

XV Research and Development:

Revenue expenditure on Research and Development is charged to statement of profit and loss in the year in which it is incurred. Capital expenditure on research and development is considered as an addition to property, plant and equipment/intangible assets.

XVI Dividend Distribution:

Dividend distribution to the company's equity holders is recognized as a liability in the company's annual accounts in the year in which the dividends are approved by the company's equity holders

A Payable is classified as a 'trade payable' if it is in respect of the amount due on account of goods purchased or services received in the normal course of business. These amounts represent liabilities for goods and services provided to the company prior to the end of the financial year which are unpaid. These amounts are unsecured and are usually settled as per the payment terms stated in the contract. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period.

A receivable is classified as a 'trade receivable' if it is in respect of the amount due to account of goods sold or services rendered in the normal course of business.

XVIII Government Grants :

Government grants are recognised at their fair value where there is a reasonable assurance that the grant will be received and the Company will comply with all attached conditions

Government grants relating to the purchase of property, plant and equipment are included in liabilities as deferred income and are credited to the statement of

profit and loss in a systematic basis over the expected life of the related assets and presented within other 'income.

Government grants relating to income are deferred and recognised in the statement of profit and Loss over the period necessary to match them with the costs

that they are intended to compensate and presented within other income.

XIX EARNINGS PER SHARE

Basic earnings per share is calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

XX Measurement of EBITDA

The Company has opted to present earnings before interest (finance cost), tax, depreciation and amortisation (EBITDA) as a separate line item on the face of the Statement of Profit and Loss for the period. The company measures EBITDA based on profit/(loss) from continuing operations.

XXI Previous Year Figures

Previous Year's figures are regrouped / rearranged wherever required.



VALIANT LABORATORIES LIMITED Proporty, Plant and Equipment

Particulars	Lasehold	Buildings	Plant & Equipments	Plant & Equipments Energy Saving Device	Electric Installation	Laboratory Testing Equipments	Furniture & Fixture	Vehicles	Office Equipments	Computers	Total	Capital Work in Progress (CWIP)
Year ended March 31, 2021 Gross carrying amount												
Opening gross carrying amount as at April 1, 2020	32.00	80.70		0.01	1.32	0.29	0.40	7.93	0.46	0.05	7.800	
Addition	•	5.02	10.92		0.05	0.34	0.14	010		0.13	16.69	
Assets capitalised during the year from CWIP							Fig			0.12	10.01	
Copyonis		,		4		1	t		,		1	
Closing gross carrying am count	32.00	85.72	116.53	10.01	1.37	0.63	0.54	8.03	0.46	0.17	245.46	
Accumulated depreciation												
Opening accumulated depreciation		8.07			0.30	0.04	NUO	110		0000	2 20	
Depreciation charge during, the year		7.76	15.10	000	0.18	0.00	0.05	1.13	0.00	0.02	04.07	
Disposals					-	0.00	COVO	Trop		0.00	24.3	
Closing accumulated depreciation		15.84	30,95	0.00	0.37	0.13	0.00	292		000	70.00	
Net carrying amount year sended March 31, 2021	32.00	88.69			1.00	020	0.45	002	000	000	1.61	
Year ended March 31, 2022 Gross carrying amount					2007	0000	0.40	3.02		60.0	195.70	
Opening gross carrying amount as at April 1, 2021	32.00	8572			70.1	67.6	100	000				
Addition	12 99	11 32	33.06	10:0	1.37	0.00	0.04	8.03	0,46	0.17	245.46	
Assets capitalised during the year from CWIP	100	2011			0.24	0.03	0.07	3.21		0.18	50.2	14.45
Disposals		1.80			0.47			1.20				
Closing gross carrying amenunt	44.99	95.24	134.59	THU U	115	990	0.61	0.7.1		. 0	6.7	
Accumulated depreciation					CATA	0000	TO'O	¥6.7		0.35	0/./87	14.45
Opening accumulated depr-eciation		15.84			0.37	010	90.0	c		000		
Depreciation charge during, the year	8.40	497	8 52	000	0.37	0.10	0.09	77.7		0.08	49.77	
Disposals		(0,61)			000	0.07	0.05	08.0	0.05	0,06	23.13	m 2
Closing accumulated depreciation	8.40	20.19			0.00	010	0.00	(1.27)		(0.00)	(2.93)	(6)
Net carrying amount year sended March 31, 2022	36.59	75.05	11.70	000	330	0.47	#1.0	FO'I	0.09	0.14	69.96	
Year ended March 31, 2023 Gross carrying amount					0000	O.P.	0.47	N.1.		0.22	217.73	14.45
Opening gross carrying am-ount as at April 1, 2022	44.99	AC 70		50.0		200		i		1		
Addition		559	50.36		48	00'0	0.01	#5%	0.57	0.35	287.70	14.45
Assets capitalised during the year from CWIP					C#-1		0.52		0.39	0.29	58.60	
Disposals			2002								29.03	
Closing gross carrying amount	44.99	100.82	211.02	100	096	990	113	200			2.96	
Accumulated depreciation					00.2	000	CTT	40.7	0.95	0.03	372.31	0.46
Opening accumulated depr-eciation	8.40	2019	38.49	000	070	0.10	210	0				
Depreciation charge during, the year	0.73	3.00			25.0	0.13	U.14	601	0.09	0.14	96,96	6
Disposals		and a			U.IO		80.0	0.91		0.14	13.95	io (
Closing accumulated depreciation	9.12	23.28		0.00	0.63	0.19	0000	27.0		90.0	(2.36)	(6)
Net carrying amount year ended March 31, 2023	35.87	77 55	16.531		40 6	CTO	Viete C	C1.77	0.20	0.20	80.96	
	10100	2000			1.50	V.9./	16.0	6.79		0.36	291.41	0.46



5- Right-of-Use Asset-	(Rs In Mn.)
Particulars	ROU
Year ended March 31, 2021 Gross carrying amount	
Opening gross carrying amount as at April 1, 2020	5.72
Addition	-
Assets capitalised during the year from CWIP	-
Disposals	-
Closing gross carrying amount	5.72
Accumulated depreciation	
Opening accumulated depreciation	1.76
Depreciation charge during the year	1.76
Disposals	-
Closing accumulated depreciation	3.53
Net carrying amount year ended March 31, 2021	2.19
Year ended March 31, 2022Gross carrying amount	
Opening gross carrying amount as at April 1, 2021	5.72
Addition	4.11
Assets capitalised during the year from CWIP	-
Disposals	-
Closing gross carrying amount	9.83
Accumulated depreciation	
Opening accumulated depreciation	3.53
Depreciation charge during the year	1.77
Disposals	-
Closing accumulated depreciation	5.30
Net carrying amount year ended March 31, 2022	4.54
Year ended March 31, 2023 Gross carrying amount	
Opening gross carrying amount as at April 1, 2022	9.83
Addition	5.42
Assets capitalised during the year from CWIP	
Disposals	
Closing gross carrying amount	15.25
Accumulated depreciation	
Opening accumulated depreciation	5.30
Depreciation charge during the year	1.68
Disposals	
Closing accumulated depreciation	6.97
Net carrying amount year ended March 31, 2023	8.28
Amortisation includes impact of Incremental Rent and additional Le	pase agreement
executed during the relevant period.	ase agreement
executed daring the relevant period.	
20. 11/4	
	A .
E MOMEAL ?	
33272 12	

Investment

March 31, 2023	March 31, 2022	March 31, 2021
	-	
-		
0.10	-	
010	-	
	0.10	0.10

Disclosure pursuant to Ind AS 27 - Separate Financial Statements

Investments in the following subsidiaries are accounted at cost Name of the Subsidiary	Principal Activity	Country of		% of equity interest	
ivasire of the dubbattanty		Incorporation	As at 31st March 2023	As at 31st March 2022	As at 31st March 2021
Valiant advanced sciences private limited	Manufacturing -	India	100.00	-	

Current Investments as restated Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Short Term Investment			
Other Investments - in Equity share (Quated)			
Investment in Equity Shares (Quoted) - Measured at FVOCI			
- Benchmark Bankbees	-	4.02	
Mutual Fund -measured at FVTPL			
- Kotak Liquid Regular growth fund	165.95	-	
- SBI Liquid Regular growth fund	174.24	-	
Total	340.19	4.02	

	No of Shares/Units of Mutual Funds	March 31, 2023	No of Shares/Units of Mutual Funds	March 31, 2022	No of Shares/Units of Mutual Funds	March 31, 2021
nvestments - in Equity Shares (Quoted)						
Other Companies - measured at FVOCI - Benchmark Bankbees			11,000	4.02		
lutual Fund -measured at FVTPL - Kotak Liquid Regular growth fund	35,441	165.95				
- SBI Liquid Regular growth fund	48,236	174.24	2	-	-	
otal	83,677	340.19	11,000	4.02		

Aggregate value of quoted investments and its market value is Rs. 340.19 lakhs (PY 4.02 lakhs).

7 Financial Assets
7A Other Non-current Financial Assets as restated

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Security Deposits Unsecured, Considered Good	7.02	6.10	5.96
Total	7.02	6.10	5.96

7B Current Financial Assets as restated

Pan	ticulars	March 31, 2023	March 31, 2022	March 31, 2021
Ins	urance Receivable	7.22	7.30	
Tol		7.22	7.30	-

8 Other Non Current Assets as restated

March 31, 2023	March 31, 2022	March 31, 2021	
0.68		0.39	
0.68	7.33	0.39	
	0.68	0.68 7.33	

March 31, 2023	March 31, 2022	March 31, 2021
		30.66
20.58	26.78	19.90
30.28	21.68	8.82
0.24	0.60	1.23
0.58	0.12	0.12
130.42	158.04	60.73
	0.24 0.58	78.74 108.87 20.58 26.78 30.28 21.68 0.24 0.60 0.38 0.12

Goods in Transit					
Particulars	March 31, 2023	March 31, 2022	March 31, 2021		
Raw Material (In Transit Stock)	4.87	21.64	-		
Total	4.57	21.64			

10 Trade Receivable as restated

Particulars Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Trade receivables	888.12	1,107.69	425.12
Less: Impairment Allowance	(2.44)	72	-
Trade Receivables (net)	885.68	1,107.69	425.12
Break-up of security details			
(i) Unsecured, considered good	885.68	1,107.69	425.12
(ii) Unsecured, credit impaired	2.44	-	
	888.12	1,107.69	425.12
Less: Impairment Allowance	(2.44)		
TOTAL	\$85.68	1,107.69	425.13

Notes

a. Due to the short nature of credit period given to customers, there is no financing component in the contract.
b. Trade receivables has been taken as certified by the management of the company.
c. Provisioning for expected credit loss has been done as per the guidance of Ind AS 109.
d. For details of Trade Receivables with related party, refer note no. 40 Related Party disclosure.
e. Trade receivables are generally non interest bearing.

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Balance at the beginning of the year			-
Allowances / (write back) during the year	24.41	16.69	
Written off against past provision		(16.69)	
Balance at the end of the year	24.41		



7. Trade receivables (current) ageing :

Particulars

As at 31 March, 2023

(i) Undisputed Trade Receivables - considered good (ii) Undisputed Trade Receivables - credit impaired (iii) Disputed Trade Receivables - considered good (iv) Disputed Trade Receivables - credit impaired	880.35	4.60	1.00	-	-	2.17	88
(iii) Disputed Trade Receivables- considered good	1						
of Dismited Trade Receivables - credit impaired	1						
) Disputed Time Internation	880.35	4.60	1.00		-	2.17	88
abilled Trade Receivables	884.65	7.00	1.00				
ss: Impairment Allowance							\$8
al Trade Receivables							
s at 31 March, 2022							
Particulars	Outstanding for follow	wing periods from	due date of payment	1-2 Year	2-3 Year	More than 3 Year	Total
	Not Due	Less than 6 Month	6 Month to 1 Year	1-2 Year	2-3 1 Car	More than 3 rem	
Undisputed Trade Receivables - considered good	988.77	96.65	17.71	-	-	4.56	1,10
i) Undisputed Trade Receivables - credit impaired							
ii) Disputed Trade Receivables - considered good v) Disputed Trade Receivables - credit impaired					100		
	988.77	96.65	17.71	-		4.56	1,10
nbilled Trade Receivables ess: Impairment Allowance							
ess: Impairment Allowance otal Trade Receivables							1,10
				The Management of the Control of the			
As at 31 March, 2021							1
Particulars	Outstanding for follow	wing periods from	due date of payment	1-2 Year	2-3 Year	More than 3 Year	Total
	Not Due	Less than 6 Month	6 Month to 1 Year	1-2 rear	2-3 1Eat	More than 5 1cm	
) Undisputed Trade Receivables - considered good	385.69	32.57	0.96	0.12	0.52	5.25	42
i) Undisputed Trade Receivables - credit impaired						1	
ii) Disputed Trade Receivables- considered good v) Disputed Trade Receivables - credit impaired							
	385.69	32.57	0.96	0.12	0.52	5.25	4:
nbilled Trade Receivables							
A Marragos							
							42
							4
otal Trade Receivables							
otal Trade Receivables Cash and Cash Equivalents as restated	Particulars	11.00 FO DE TAL ON SE DE TA			March 31, 2023	March 31, 2022	
otal Trade Receivables Cash and Cash Equivalents as restated Cash and Cash Equivalents	Particulars				March 31, 2023	March 31, 2022	March 31, 20
Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand	Particulars				3.21 0.55	0.11 1.20	March 31, 20
Cash and Cash Equivalents as restated Cash and Cash Equivalents (ash and Cash Equivalents () Balances with banks () Cash on hand	Particulars				3.21	0.11	March 31, 20
Cash and Cash Equivalents as restated Cash and Cash Equivalents as Balances with banks b) Eash on hand Cotal	ed				3.21 0.55 3.76	0.11 1.20 1.31	March 31, 20
Cash and Cash Equivalents as restated Cash and Cash Equivalents as Balances with banks b) Eash on hand Cotal					3.21 0.55	0.11 1.20	March 31, 20
Cosh and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Total Sank Balances Other than Cash & Cash Equivalents as restate Other Balances with Banks	ed				3.21 0.55 3.76 March 31, 2023	0.11 1.20 1.31 March 31, 2022	March 31, 20
Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Fotal Sank Balances Other than Cash & Cash Equivalents as restate Other Balances with Banks Salances with Banks	ed				3.21 0.55 3.76 March 31, 2023	0.11 1.20 1.31 March 31, 2022	March 31, 202
Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Fotal Sank Balances Other than Cash & Cash Equivalents as restate Other Balances with Banks Salances with Banks	ed				3.21 0.55 3.76 March 31, 2023	0.11 1.20 1.31 March 31, 2022	March 31, 20 March 31, 20
Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Fotal Sank Balances Other than Cash & Cash Equivalents as restate Other Balances with Banks Salances with Banks Total	ed Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.80	0.11 1.20 1.31 March 31, 2022 200.00 200.00	March 31, 20 March 31, 20 11
Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Fotal Sank Balances Other than Cash & Cash Equivalents as restate Other Balances with Banks Salances with Banks Total	ed Particulars				3.21 0.55 3.76 March 31, 2023	0.11 1.20 1.31 March 31, 2022	March 31, 20 March 31, 20 11
Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Total Sank Balances Other than Cash & Cash Equivalents as restate Other Balances with Banks Salances with Banks Cotal Current Financial Assets - Loans as restated (at amortised or	ed Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.80	0.11 1.20 1.31 March 31, 2022 200.00 200.00	March 31, 20. March 31, 20. 11: 15 As at 31st Mar
Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Total Sank Balances Other than Cash & Cash Equivalents as restate Other Balances with Banks Balances with Banks Could Current Financial Assets - Loans as restated (at amortised or Jinsecured, Considered Good Can to Employees	ed Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.50 March 31, 2023	0.11 1.20 1.31 March 31, 2022 200.00 200.00	March 31, 20 March 31, 20 1: 1: As at 31st Mar
Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Fotal Sank Balances Other than Cash & Cash Equivalents as restated Other Balances with Banks Salances with Banks Cotal Current Financial Assets - Loans as restated (at amortised of control of the Cash Cash Cash Cash Cash Cash Cash Cash	ed Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.50 March 31, 2023	0.11 1.20 1.31 March 31, 2022 200.00 200.00 As at 31st March, 2022	March 31, 20 March 31, 20 11: 15: As at 31st Mar 2021
Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Fotal Sank Balances Other than Cash & Cash Equivalents as restated Other Balances with Banks Salances with Banks Cotal Current Financial Assets - Loans as restated (at amortised of control of the Cash Cash Cash Cash Cash Cash Cash Cash	ed Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.50 March 31, 2023	0.11 1.20 1.31 March 31, 2022 200.00 200.00 As at 31st March, 2022	March 31, 20 March 31, 20 1: 15 As at 31st Mar 2021
Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Fotal Sank Balances Other than Cash & Cash Equivalents as restate Sank Balances with Banks Salances with Banks Cotal Lurrent Financial Assets - Loans as restated (at amortised co	ed Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.50 March 31, 2023	0.11 1.20 1.31 March 31, 2022 200.00 200.00 As at 31st March, 2022	March 31, 20 March 31, 20 11: 15: As at 31st Mar 2021
Total Trade Receivables Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Fotal Bank Balances Other than Cash & Cash Equivalents as restate Sank Balances with Banks Salances with Banks Cotal Current Financial Assets - Loans as restated (at amortised co Jinsecured, Considered Good Con to Employees divance to Related Parties Total	ed Particulars Particulars ost) Particulars				3.21 0.53 3.76 March 31, 2023 0.80 0.50 March 31, 2023	0.11 1.20 1.31 March 31, 2022 200.00 200.00 200.00 0.01 0.01	March 31, 20 March 31, 20 1: 12 As at 31st March 2021
Total Trade Receivables Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Total Sank Balances Other than Cash & Cash Equivalents as restate Dither Balances with Banks Balances with Banks Cotal Current Financial Assets - Loans as restated (at amortised of Unsecured, Considered Good Oan to Employees Advance to Related Parties Total Other Current Assets as restated	ed Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.80 0.80 March 31, 2023 March 31, 2023		March 31, 20 March 31, 20 1 1: As at 31at March 31, 20 March 31, 20
Cash and Cash Equivalents as restated Cash and Cash Equivalents (a) Balances with banks (b) Cash on hand Total Bank Balances Other than Cash & Cash Equivalents as restated Other Balances with Banks Balances with Banks Balances with Banks Cotal Current Financial Assets - Loans as restated (at amortised of the Cash Equivalents as restated (a	ed Particulars Particulars ost) Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.50 March 31, 2023 March 31, 2023	March 31, 2022 As at 31st March, 2022 O.01 March 31, 2022 March 31, 2022 Jone 1 March 31, 2022	March 31, 20 March 31, 20 1 1: As at 31st Mar 2021
Cash and Cash Equivalents as restated Cash and Cash Equivalents (a) Balances with banks (b) Cash on hand Total Bank Balances Other than Cash & Cash Equivalents as restated Other Balances with Banks Balances with Banks Balances with Banks Courrent Financial Assets - Loans as restated (at amortised of the Cash Cash Equivalents as restated Unsecured, Considered Good Cont to Employees Advance to Related Parties Total Other Current Assets as restated Other Current Assets Salance with Statutory / Government Authorities **Pepaid Expenses Advances to Suppliers	ed Particulars Particulars ost) Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.80 0.80 March 31, 2023 March 31, 2023		March 31, 20 March 31, 20 1 1: As at 31st May 2021
Total Trade Receivables Cash and Cash Equivalents as restated Cash and Cash Equivalents a) Balances with banks b) Cash on hand Total Sank Balances other than Cash & Cash Equivalents as restate Cher Balances with Banks Salances with Banks Total Current Financial Assets - Loans as restated (at amortised of the Current Financial Assets - Loans as restated (at amortised of the Current Financial Assets - Loans as restated (at amortised of the Current Financial Assets - Loans as restated (at amortised of the Current Assets as restated Other Current Assets as restated Other Current Assets as restated Other Current Assets sa restated	ed Particulars Particulars ost) Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.80 0.80 0.70 3.23.33 328.03	As at 31st March, 2022 March 31, 2022 200.00 200.00 As at 31st March, 2022 0.01 0.01 March 31, 2022	March 31, 20 March 31, 20 1 1 1 As at 31st March 2021
Total Trade Receivables Cash and Cash Equivalents as restated Cash and Cash Equivalents (a) Balances with banks (b) Cash on hand Total Bank Balances other than Cash & Cash Equivalents as restate Other Balances with Banks Balances with Banks Total Current Financial Assets - Loans as restated (at amortised of the Cash of t	ed Particulars Particulars ost) Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.80 0.80 March 31, 2023 March 31, 2023 63.20 5.19	As at 31st March, 2022 March 31, 2022 As at 31st March, 2022 March 31, 2022 March 31, 2022	March 31, 20 March 31, 20 1 1 1 As at 31st March 2021
Cash and Cash Equivalents as restated Cash and Cash Equivalents (as particular as a continuous continuous) Cash and Cash Equivalents (as Balances with banks (b) Cash on hand Total Bank Balances Other than Cash & Cash Equivalents as restated (b) Cash Equivalents (c) Cash Equivalents (c	ed Particulars Particulars ost) Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.80 0.80 0.70 3.23.33 328.03	As at 31st March, 2022 March 31, 2022 200.00 200.00 As at 31st March, 2022 0.01 0.01 March 31, 2022	March 31, 20 March 31, 20 1 1: As at 31st March 2021 March 31, 20
Less: Impairment Allowance Total Trade Receivables Cash and Cash Equivalents as restated Cash and Cash Equivalents (a) Balances with banks (b) Cash on hand Total Bank Balances Other than Cash & Cash Equivalents as restated Other Balances with Banks Total Current Financial Assets - Loans as restated (at amortised of Cash Equivalents as restated) Current Financial Assets - Loans as restated (at amortised of Cash Equivalents as restated) Current Financial Assets - Loans as restated (at amortised of Cash Equivalents as restated) Current Financial Assets - Loans as restated (at amortised of Cash Equivalents as restated) Current Financial Assets - Loans as restated Other Current Assets as restated Other Current Assets Salance with Statutory / Government Authorities **repaid Expenses** University Tax Assets - Loans Assets - Loans Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at a mortised of Cash Equivalents) Cash and Cash Equivalents (at	ost) Particulars ost) Particulars Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.80 0.50 March 31, 2023 March 31, 2023 March 31, 2023	As at 31st March, 2022 March 31, 2022 200.00 200.00 As at 31st March, 2022 0.01 March 31, 2022 March 31, 2022	March 31, 20 March 31, 20 1 1: As at 31st March 31, 20 March 31, 20
Cash and Cash Equivalents as restated Cash and Cash Equivalents (a) Balances with banks (b) Cash on hand Total Bank Balances with banks (b) Cash Equivalents as restated Other Balances with Banks Balances with Banks Balances with Banks Courrent Financial Assets - Loans as restated (at amortised of the course of th	ed Particulars Particulars ost) Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.80 0.80 0.70 3.23.33 328.03	As at 31st March, 2022 March 31, 2022 200.00 200.00 As at 31st March, 2022 0.01 0.01 March 31, 2022	March 31, 20 March 31, 20 1 1: As at 31st March 31, 20 March 31, 20
Cash and Cash Equivalents as restated Cash and Cash Equivalents (as particular as a continuous continuous) Cash and Cash Equivalents (as Balances with banks (b) Cash on hand Total Bank Balances Other than Cash & Cash Equivalents as restated (b) Cash Equivalents (c) Cash Equivalents (c	ost) Particulars Particulars Particulars Particulars				3.21 0.55 3.76 March 31, 2023 0.80 0.80 0.50 March 31, 2023 March 31, 2023 March 31, 2023	As at 31st March, 2022 March 31, 2022 200.00 200.00 As at 31st March, 2022 0.01 March 31, 2022 March 31, 2022	March 31, 20 March 31, 20 11: 15: As at 31st Mar 2021

Outstanding for following periods from due date of payment

Not Due Less than 6 6 Month to 1 Year

Month

Total

More than 3 Year

2-3 Year

1-2 Year

Authorised Share Capital as Restated

(Rs In Mn.)

Particulars	March 31, 2023	March 31, 2022**	March 31, 2021**
(a) Authorised 4,50,00,000 Equity Shares of Rs. 10/- each	450.00	230.00	230.00
(b) Issued 3.25,60,000 Equity Shares of Rs. 10 each	325.60	162.80	105.00
(c) Subscribed and fully paid up 3,25,60,000 Equity Shares of Rs. 10 each	325.60	162.80	105.00
Total	325.60	162.80	105.00

Rights, Preferences and Restrictions attached to equity shares:

Rights, Preterences and Restrictions attached to equity shares:
Equity Shares are issued consequent to conversion of Partnership firm to Company formed as per provisions of Companies Act,2013. Wherein Partners of firm has subscribed to Equity Shares of the Company. The Company has one class of equity shares having a par value of Rs.10 each. The Shareholders are entitled to receive dividend in proportion to the amount of paid up equity shares held by them. The Company has not declared any dividend during the year. Each shareholder is entitled to vote in proportion to his share of paid up equity share capital of the Company, except in case of voting by show of hands where each shareholder present in person shall have one vote only. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts.

Issued Subscribed & Paid Un

(Rs In Mn.)

Particulars	March 31, 2023	March 31, 2022**	March 31, 2021**
Equity Share Capital	162.80	105.00	105.00
Add: Issue of Shares - Right issue	-	43.00	-
Add: Issue of Bonus shares (1:1) (P.Y. Bonus issue (1:10))	162.80	14.80	-
3,25,60,000 Equity Shares of Rs. 10 each	325.60	162.80	105.00

Reconciliation of Shares outstanding at the beginning and at the end of the period

(No of share)

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
No. of Share outstanding at the beginning of the period/year	1,62,80,000	1,05,00,000	1,05,00,000
Add: Issue of Shares - Right issue	-	43,00,000	
Add: Issue of Bonus shares (1:1) (P.Y. Bonus issue (1:10))	1,62,80,000	14,80,000	
No of Share outstanding at the end of the period/year	3,25,60,000	1,62,80,000	1,05,00,000

Details of shareholders holding more than 5% of aggregate shares capital (In terms of number of shares)

(No of chare)

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Name of Shareholders	No of Share Held	No of Share Held	No of Share Held
-Dhanvallabh Ventures LLP	2,03,50,000	1,01,75,000	71,92,500
- Paresh Shashikant Shah	40,67,690	20,33,845	11,01,450
- Shantilal Shivji Vora	32,59,190	16,29,595	7,33,950
- Santosh Shantilal Vora	32,59,190	16,29,595	7,33,950
-Kanchan Shantilal Vora	16,14,690	8,07,345	7,33,950
Total	3,25,50,760	1,62,75,380	1,04,95,800

Datails of shareholders holding more than 50% of aggregate shares capital (In terms of number of 0% holding)

Particulars	March 31, 2023	March 31, 2022	March 31, 2021 % Holding	
Name of Shareholders	% Holding	% Holding		
-Dhanvallabh Ventures LLP	62.50%	62.50%	68.50%	
- Paresh Shashikant Shah	12.49%	12.49%	10.49%	
- Shantilal Shivji Vora	10.01%	10.01%	6.99%	
- Santosh Shantilal Vora	10.01%	10.01%	6.99%	
-Kanchan Shantilal Vora	4.96%	4.96%	6.99%	
Total	100%	100%	100%	

Details of promoters holding shares			(No of share)
Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Name of Shareholders	Number	Number	Number
-Dhanvallabh Ventures LLP	2,03,50,000	1,01,75,000	71,92,500
- Shantilal Shivji Vora	32,59,190	16,29,595	7,33,950
Total	2,36,09,190	1.18.04.595	79.26.450

Details of promoters holding shares

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Name of Shareholders	% Holding	% Holding	% Holding
-Dhanvallabh Ventures LLP	62.50%	62.50%	68.50%
- Shantilal Shivji Vora	10.01%	10.01%	6.99%
Total	72.51	72.51	75.49

Promoters do not hold any class of shares other than stated above.



Other Equity			(Rs In Mn.)
Particulars	March 31, 2023	March 31, 2022	March 31, 2021
a. Security Reserve	163.39	326.19	
b. Retained Earning	515.91	225.61	780.82
Total, Other Equity	679.30	551.80	780.82

 Security Reserve

 Particulars
 March 31, 2023
 March 31, 2022
 March 31, 2021

 Opening Balance
 326.19

 Add - Security premium during the year
 340.99

 Less - Bonus Issue during the year
 (162.80)
 (14.80)

 Closing Balance
 163.39
 326.19

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Retained Earning			
Opening Balance (Surplus in Profit & Loss)	225.61	780.82	281.24
Add: Net Profit for the year	289.98	274.96	305.93
Add / (Less): Transactions in Current Capital Accounts **	-	(487.37)	193.65
Add / (Less): Transfer to secueity premium from partner's capital		(340.99)	
Less: Remeasurement (Loss) on defined benefit plan (net off tax)	0.32	(1.50)	-

515.91

515.91

225.92

(0.31)

225.61

780.82

780.82

17

Amount available for appropriation

Expenses incurred for issuance of Bonus Shares

Appropriation:

Closing Balance

The above statement should be read with the notes to restated summary statements of assets and liabilities, profits and losses and cash flows appearing in Annexure I, Π and Π I.



^{**} The transactions in Partners Capital Accounts other than transfer of Profits have been shown in Adjustment in statement of Profit and Loss to make the Ind AS statements comparable

[.] The figures disclosed above are based on the restated summary of assets and liabilities of the company.

18 Borrowings

Non-current Borrowing as restated			(Rs In Mn.
Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Non-Current Liabilities-Financial Liabilities			
Borrowings-Non Current			
a- Secured			
TERM LOANS			
'- Foreign currency loan			
'- Indian currency loan- Bank of baroda*	-	-	2.74
b- Unsecured			
From Related Party			
'- Indian currency loan	594.00	594.00	-
Total	594.00	594.00	2.74

Terms and conditions:

Secured Loan

Lender	Nature of facility	Sanction Amount	Amount o/s as at 31/03/2023	Rate of Intere st	Repayment terms	Principle terms & conditions
					Rs 80,316 and 84	
Bank of Baroda	Vehicle loan	49,92,000.00	-	8.75%	Month	NA

vehicle loan from April 2019 to August 2021

18B Current Borrowing as restated

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Borrowings-Current			
Repayable on demand from Banks (secured)			
- Cash Credit Facility		12.81	-
Current Maturity of Long Term Debt (secured)			
- Indian currency loan		-	0.77
Total		12.81	0.77

Footnotes:

Working capital facilities from banks as at March 31, 2022 amounting to Rs. Nil (P.Y - 128.07 Lakhs) were secured by a first pari passu charge on the stock of raw materials, finished goods, stock in process, consumable stores, book debts of the Company & Immovable Property - Factory Land & Building at L-13, L-28, L-28PT, L-29 and L-30 at MIDC Tarapur. These credit facilities carry average interest rates in the range of 6.50% to 9.50% (31 March, 2022: 6.50% to 9.50%).

The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

There are no material differences between the quarterly statements of stock filed by the company with banks and the books of accounts.

The Company has not been declared as a wilful defaulter by any bank or financial institution or other lender in accordance with the guidelines on wilful defaulters issued by the Reserve Bank of India.

19 Lease Liability 19A Non-current as

Non-current as restated

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Lease Liability			
Lease Liability	6.42	2.67	0.58
Total	6.42	2.67	0.58

19B Current as restated

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
		-	
Lease Liability	1.75	1.78	1.95
Total	1.75	1.78	1.95
Footnotes:	1.73	1.70	

The Company has lease contracts for its office premises and godowns with lease term between 1 year to 3 years. The Company's obligations under its leases are secured by the lessor's title to the leased assets. Generally, the Company is restricted from assigning and subleasing the leased assets. The Company also has certain leases of office premises and godowns with lease terms of 12 months or less. The Company applies the 'short-term lease' recognition exemptions for these leases.

The movement in lease liabilities during the year ended as follows:

	March 31, 2023	March 31, 2022	March 31, 2021
Balance at the beginning	4.45	2.54	4.39
Additions	5.23	3.92	1.07
Accretion of interest	0.52	0.18	0.34
Payment of lease liabilities	2.03	2.18	0.34 2.19
Balance at the end	8.18	4.45	2.54
Non-current	6.42	2.67	0.58
Current	1.75	1.78	1.95

The following are the amounts recognised in profit or loss:

	March 31, 2023	March 31, 2022	March 31, 2021
Depreciation on right-of-use assets	1.68	1.77	170
Interest expense on lease liabilities	0.52	1.77	1.76
Expense relating to short-term leases		0.18	0.34
Total amount recognised in statement of profit and loss	1.20	1.20	1.20
Total amount recognised in statement of profit and loss	3.40	3.14	3.30



Particulars	March 31, 2023	March 31, 2023 March 31, 2022				
Other Financial Liabilities						
Security Deposit Received	9.61	9.61	9.61			
Total	9.61	9.61	9.61			

21 Provisions

21A Non-current

	March 31, 2023	March 31, 2022	March 31, 2021
Provision for Leave Salary	0.78		_
Total amount recognised in statement of profit and loss	0.78	-	-

21B Current

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Provision			
Provision for Gratuity	(0.46)		
Provision for Leave Salary	0.05		
Provision for Bonus	1.59	1.56	1.26
Total	1.18	1.56	1.26

INCOME TAXES

22 Deferred Tax

Major components of deferred tax liabilities/(assets) arising on account of timing difference: As at 31st March, 2023

Particulars		Charge / (Credit) to Statement of Profit and Loss		As on 31st March, 2023
Deferred tax liabilities, on account of:				
Difference between WDV of depreciable fixed assets as per the books	2.80	4.88		7.69
Deferred tax assets, on account of:				-
Provision for expense allowed for tax purpose on payment basis (Net)	-	(4.95)		(4.95)
Remeasurement of the defined benefit plans through OCI	0.05	(0.32)		(0.27)
Difference in carrying value and tax base of investments in equity	- 1	4.09		4.09
Difference in Right-of-use asset and lease liabilities	0.10	-		0.10
Deferred tax expense/(benefit) for the year		3.70	-	-
Net Deferred tax liabilities	2.96			6.66

As at 31st March, 2022

Particulars	As on 1st April, 2021	Charge / (Credit) to Statement of Profit and Loss	As on 31st March, 2022
Deferred tax liabilities, on account of:			
Difference between WDV of depreciable fixed assets as per the books of accounts and Income Tax Act, 1961 Deferred tax assets, on account of:	5.45	(2.65)	2.80
Provision for expense allowed for tax purpose on payment basis (Net)			
Remeasurement of the defined benefit plans through OCI Difference in carrying value and tax base of investments in equity instruments measured at EVTOCI		0.05	0.05
Difference in Right-of-use asset and lease liabilities Deferred tax expense/(benefit) for the year	0.06	0.04 (2.54)	0.10
Net Deferred tax liabilities	5.51		2.96

As at 31st March, 2021

As on 1st April, 2020	Charge / (Credit) to Statement of Profit and Loss	Charge/ (Credit) to Other Comprehensive Income	As on 31st March, 2021
5.79	(0.34)		5.45
-			
0.02	0.04		
0.02	No. of the last of		0.06
5.91	(0.30)	-	5.51
	5.79	2020 Statement of Profit and Loss 5.79 (0.34)	Statement of Profit and Loss (Credit) to Other Comprehensive Income



The major components of Income Tax Expense for the year:

	March 31, 2023	March 31, 2022	March 31, 2021
(i) Income tax recognised in the Statement of Profit and Loss			
Current tax:			
For current year	88.00	144.68	165
Deferred tax:			
For current year	3.38	(2.60)	
Income tax expense recognised in the Statement of Profit and Loss	91.38	142.08	164.30
(ii) Income tax expense recognised in Other Comprehensive Income			
Deferred tax:	_		
Income tax (expense) / benefit on remeasurement of defined benefit plans	0.32	(0.05)	-
Income tax benefit / (expense) recognised in OCI	0.32	(0.05)	-

Reconciliation of tax expense and accounting profit for the year:

	March 31, 2023	March 31, 2022	March 31, 2021
Profit before tax	381.36	417.04	470.23
Income tax expense calculated at 25.168% and partnership Rate 34.32%	95.98	116.65	161.38
Tax effect on non-deductible expenses	5.52	4.07	2.91
Effect of Income which is taxed at special rates	2.83	-	
Effect of concessions (depreciation under income tax act)	(7.34)	8.55	-
Others	(8.99)	15.40	0.30
Total	88.00	144.68	164.60
Tax expense as per Statement of Profit and Loss	88.00	144.68	164.60

The tax rate used for reconciliation above is the corporate tax rate of 25.168% payable by corporate entities in India on taxable profits under Indian tax law and earier this is partnership firm rate This rate is applicable subject to certain conditions, including that the total income should be computed without claiming specific deduction or exemptions.

23 DETAILS OF TRADE PAYABLES AS RESTATED

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Trade & Non-Trade Payables			
(a) Total Outstanding Dues of Micro enterprises and Small Enterprises; and	0.06	0.18	
(b) Total Outstanding dues of Creditors other than Micro enterprises and small enterprises	472.90	464.19	122.92
Total	472.96	464.37	122,92
(a) Principal amount remaining unpaid to any supplier	0.06	0.18	
(b) Interest on (i)(a) above	-	-	-
The amount of interest paid along with the principal payment made	-	-	
Amount of interest due and payable on delayed payments	-	-	
Amount of further interest remaining due and payable for the earlier years	-	-	
Total outstanding dues of Micro and Small Enterprises	-	_	-
- Principal	0.06	0.18	
- Interest			

^{*} The disclosures under the Micro, Small and Medium Enterprises Development Act, 2006 have been made in respect of such vendors to the extent they could be identified as micro and small enterprises on the basis of information available with the Company.

Trade payables ageing:

As at 31st March, 2023

Particulars	Outstanding for the following periods from due date of payment						
	Unbilled	Not Due	<1 year	1 Year - 2 Years	2-3 Years	> 3 Years	TOTAL
(i) MSME (ii) Others (iii) Disputed Dues - MSME (iv) Disputed Dues - Others	-	0.06 471.77	0 0.67	0 0.26	0.20	0.00	0.0 472.9
	-	471.83	0.67	0.26	0.20	0.00	472.9

As at 31st March, 2022

Particulars		Outstanding for the following periods from due date of payment					
	Unbilled	Not Due	<1 year	1 Year - 2 Years	2-3 Years	> 3 Years	TOTAL
(i) MSME (ii) Others		0.179169					0.18
(iii) Disputed Dues - MSME		462.57	1.22	0.33	0.03	0.04	464.19
(iv) Disputed Dues - Others							
	-	462.75	1.22	0.33	0.03	0.04	464.37

As at 31st March, 2021

Particulars		Outstanding for the following periods from due date of payment						
	Unbilled	Not Due	<1 year	1 Year - 2 Years	2-3 Years	> 3 Years	TOTAL	
(i) MSME						- D ACMAD	TOTAL	
(ii) Others		121.56	121.56	0.73	0.37	0.24	0.00	100.00
(iii) Disputed Dues - MSME				0.75	0.37	0.24	0.02	122.92
(iv) Disputed Dues - Others								
	-	121.56	0.73	0.37	0.24	0.02	122.92	



4.52		1.46
		1.59
9.67		5.58
20.18	13.07	8.62
March 31, 2023	March 31, 2022	March 31, 2021
8.41	-	0.15
0.70	0.68	0.99
9.11	0.68	1.14
March 31, 2023	March 31, 2022	March 31, 2021
-		22,21
		22.21
	5.99 9.67 20.18 March 31, 2023 8.41 0.70 9.11	5.99 1.90 9.67 4.23 20.18 13.07

24 OTHER FINANCIAL LIABILITIES AS RESTATED

Particulars



March 31, 2021

March 31, 2022

March 31, 2023

27

DETAILS OF REVENUE FROM OPERATIONS AS RESTA	DETAILS OF REVENUE FROM OPERATIONS AS RESTATED (Rs In Mn)				
Particulars	For the year ended	For the	For the year ended		
	31st March, 2023	16th August 2021 to March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021**
Revenue from Operations					
Sale of Manufactured Products	3,317.48	2,078.92	813.96	2,892.89	1,805.51
Sale of Traded Products	3.62	3.52	0.82	4.34	0.18
Other revenue from operation	18.00	9.00	9.00	18.00	18.00
Total	3 339 10	2 091 44	823 70	2 915 23	1 822 60

Footnotes

Reconciliation of revenue as per contract price and as recognised in the Statement of Profit and Loss:

Particulars	For the year ended	For the	For the year ended		
	31st March, 2023	16th August 2021 to March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021**
Revenue as per contract price Less: Discount	3,339.10	2,091.44	823.79	2,915.23	1,823.69
Revenue as per the Statement of Profit and Loss	3,339.10	2,091.44	823.79	2,915.23	1,823.69

In case of Domestic Sales, payment terms range from 60 days to 100 days based on geography and customers. In case of Export Sales these are either against documents at sight, documents against acceptance or letters of credit - 60 days to 120 days. There is no significant financing component in any transaction with the customers.

The Company does not provide performance warranty for products, therefore there is no liability towards performance warranty.

The Company does not have any remaining performance obligation as contracts entered for sale of goods are for a shorter duration.

DETAILS OF OTHER INCOME AS RESTATED

Particulars	For the year ended	For the	year ended 31st March,	2022**	For the year ended
	31st March, 2023	16th August 2021 to March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021**
Interest Income					
Investments in debt instruments measured at fair value	0.06	0.03	0.03	0.06	0.08
Other financial assets carried at amortised cost	2.59	2.80	2.59	5.39	3.62
	2.65	2.83	2.62	5.45	3.70
Dividend Income					
Dividends from quoted equity investments measured at fair value through OCI	_	-	-	_	
				-	
Other Non-operating Income					
Net gains (Losses) on fair value changes through FVTPL	38.37	0.30		0.30	
Foreign Exchange gain / (loss)	5.83	1.31	7.32	8.63	10.09
Insurance claims		-	0.96	0.96	-
Sale of Scrap	-	0.09		0.09	
Miscellaneous Income	1.77	3.02	0.64	3,66	0,33
	45.97	4.73	8.91	13.64	10.43
Other Gains and Losses					
Net gain on sale of property, plant and equipment	-	0.40	-	0.40	
	-	0.40	-	0.40	-
Total	48.63	7.95	11.53	19.49	14.12

29

Particulars	For the year ended	For the	year ended 31st March,	2022**	For the year ended 31st March, 2021
	31st March, 2023	16th August 2021 to March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	
Cost of Materials Consumed					
Raw Material					
Opening Stock (including goods-in-transit)	108.87	137.31	30.66	30.66	10.94
Add: Purchases	2,734.64	1,658.04	778.49	2,436.53	1,224.90
and the second s	2,843.51	1,795.35	809.15	2,467.19	1,235.85
Less: Closing Stock (including goods-in-transit)	78.74	108.87	137.31	108.87	30.66
	2,764.77	1,686.48	671.84	2,358.32	1,205.18
Packing Materials Consumed					
Opening Stock (including goods-in-transit)	0.60	0.67	1.23	1.23	0.17
Add: Purchases	7.65	3.90	1.44	5.34	4.60
	8.24	4.57	2.67	6.57	4.78
Less: Closing Stock (including goods-in-transit)	0.24	0.60	0.67	0.60	1.23
	8.00	3.97	2.00	5.98	3.55
TOTAL	2,772.77	1,690.45	673.85	2,364,30	1,208.73

Purchase of stock in trade

Furchase of stock in trade					
Particulars	For the year ended	For the year ended 31st March, 2022**			For the year ended
	31st March, 2023	16th August 2021 to March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021
Purchase of stock in trade	2.83	3.22	0.38	3.60	0.11
	2.83	3,22	0.38	3.60	0.11

Particulars	For the year ended	For the	year ended 31st March,	2022**	For the year ended
	31st March, 2023	16th August 2021 to March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021
Changes in Inventories of Finished Goods & Work in Progress				Davinaci, acas	
Stock at the end of the year		_			
Finished Goods	30.28	21.68	24.78	21.68	8.82
Work-in-Process	20.58	26,78	9.28	26.78	
Total	50.86	48.45	34.06	48.45	19.90 28.71
Less : Stock at the beginning of the year					
Finished Goods	21.68	24.78	8.82	8.82	20.05
Work-in-Process	26.78	9.28	19.90	19.90	20.95 6,50
	48.45	34.06	28.71	28.71	27.45
(Increase)/decrease in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(2.41)	(14.39)	(5.34)	(19.74)	(1.27)



DETAILS OF EMPLOYEE BENEFIT EXPENSES AS RESTATED For the year ended 31st March, 2023 For the year ended 31st March, 2021 For the year ended 31st March, 2022** 1st April 2021 to 15th For the year ended 31st March, 2022 16th August 2021 to March 2022 August 2021 Employee Benefits Expense 41.19 20.64 7.12 24.20 Salaries & Wages Contribution to Provident and Other Funds 1.25 0.40 1.23 2.48 0.40 3.32 2.48 Staff welfare expenses 1.62

46.13

22,29

8.35

30.64

A. Defined benefit plans

TOTAL

32

(ii) Post-employment benefits (Gratuity)

The company provides for gratuity for employees in India as per the Payment of Gratuity Act, 1972. Employees who are in continuous service for a period of 5 years are eligible for gratuity. The amount of gratuity provides for gratuity for employees last drawn basic salary per month computed proportionately for 15 days salary multiplied for the number of years of service. The gratuity plan is a funded plan and the company makes contributions to recognized funds in India. The company maintains a target level of funding to be maintained over a period of time based on estimations of expected gratuity payments.

Aforesaid post-employment benefit plans typically expose the Company to actuarial risks such as: investment risk, interest rate risk, salary risk and longevity risk.

- (i) Investment risk: The present value of the defined benefit plan liability is calculated using a discount rate determined by reference to government bond yields. If the return on plan asset is below this rate, it will create a plan deficit.
- (ii) Interest risk: A decrease in the bond interest rate will increase the plan liability. However, this will be partially offset by an increase in the value of plan's debt investments.
- (iii) Salary risk: The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in salary of the plan participants will

 [iv) Longevity risk: The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.

Details of defined benefit obligations and plan assets (Gratuity)

The amounts recognised in the balance sheet and the movements in the net defined benefit obligation over the year are as follows:

Particulars	For the year ended 31st March, 2023	For the year ended 31st March, 2022
Change in defined benefit obligations:		
Obligation at the beginning of the year	9.12	7.86
Current Service Cost	0.45	0.32
Interest Cost	0.66	0.54
Acturial (Gain)/Loss	(0.65)	1.46
Benefits Paid	(1.40)	(1.06)
Obligation at the end of the year	8.18	9.12

Particulars	For the year ended 31st March, 2023	For the year ended 31st March, 2022
Change in plan assets:		
Fair value of plan assets at the beginning of the year	9.20	7.77
Interest income	0.67	0.53
Remeasurement gain/(loss) excluding amount included within employee	(0.01)	
benefit expense		
Contributions by the Employer	0.19	1.95
Benefits Paid	(1.40)	(1.06)
Fair value of plan assets at the end of the year	8.64	9.20

Amounts recognised in the balance sheet consist of:

Particulars	For the year ended 31st March, 2023	For the year ended 31st March, 2022
Present Value of Obligation	8.18	9.12
Fair Value of Plan Assets	(8.64)	(9.20)
	(0.46)	(0.08)
Recognised as:		
Provision for Gratuity (non-current)	_	
Provision for Gratuity (current)	(0.46)	(0.08)

Expense/(gain) recognised in the statement of profit and loss consists of:

	For the year ended 31st March, 2023	For the year ended 31st March, 2022
Employee benefits expenses:		
Current service cost	0.45	0.32
Net interest expense	(0.01)	0.01
	0.45	0.33
Other comprehensive income		
Return on plan assets excluding amount included in employee benefits expense	0.01	(0.01)
Actuarial (gain)/loss arising from changes in experience adjustments	(0.65)	1.46
	(0.64)	1.45
Expense/(gain) recognised in the statement of profit and loss	(0.19)	1.77

The major categories of plans assets are as follows:

	For the year ended 31st March, 2023	For the year ended 31st March, 2022
Asset category		
Insurance fund	8.64	9,20
Total	8.64	9.20



27.08

	For the year ended 31st March, 2023	For the year ended 31st March, 2022
Financial Assumptions:		
Discount Rate	7.50%	7.50%
Rate of escalation in Salary	5.50%	5.50%
Demographic Assumptions:		
Rate of Employee Turnover	3.00%	3.00%
Mortality Rate	Indian Assured Lives	Indian Assured Lives
,	Mortality	Mortality
	2012-14 (Urban)	2012-14 (Urban)
	2012-14 (Urban)	2012-14 (Urban

Particulars	For the year ended 31st March, 2023	For the year ended 31st March, 2022
1st following year	0.53	1.61
2nd following year	1.07	0.66
3rd following year	0.63	1.05
4th following year	0.72	0.58
5th following year	0.76	0.67
Sum of year 6 To 10	4.00	4.17
Sum of year 6 To 10	7.00	6.63

(i) The sensitivity analysis have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

(ii) The sensitivity analysis presented above may not be representative of the actual change in the projected benefit obligation as it is unlikely that the change in assumptions would occur in isolation

(iv) The Company is expected to contribute Rs. 1.92 Lakhs (PY Rs 19.48 lakhs) to defined benefit plan obligations funds for the year ended March 31, 2023.

(v) Expected return on assets is determined by mulliplying the opening fair value of the plan assets by the expected rate of return determined at the start of the annual reporting period, taking account of expected contributions & expected settlements during the reporting period.

(vii) The Weighted Average Duration of the Plan works out to 8 years

Maturity profile of projected benefit obligation (from fund):

(viii) Asset Liability matching strategy:

(FIII) Asset Liability matching strategy:

The money contributed by the Company to the Gratuity fund to finance the liabilities of the plan has to be invested. The trustees of the plan have outsourced the investment management of the fund to an insurance Company. The insurance Company in turn manages these funds as per the mandate provided to them by the trustees and the asset allocation which is within the permissible limits prescribed in the insurance regulations. Due to the restrictions in the type of investments that can be held by the fund, it is not possible to explicitly follow an asset liability matching strategy. There is no compulsion on the part of the Company to fully prefund the liability of the Plan.

R. Defined contribution plans Provident Fund

The company has certain defined contribution plans. Contributions are made to provident fund for employees at the rate of 12% of basic salary as per regulations. The contributions are made to registered provident fund administered by the government. The obligation of the company is limited to the amount contributed and it has no further contractual nor any constructive obligation. The expense recognized during the period towards defined contribution plan are Rs 16.84 lakhs (PY Rs 13.14 lakhs).

For the year ended

DETAILS OF FINANCE COSTS AS RESTATED

	31st March, 2023	16th August 2021 to March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021
Interest Expense	2.01	0.15	0.40	0.55	17.50
Interest on finance lease obligations	0.52	0.09	0.09	0.18	0.34
TOTAL	2.54	0.24	0.49	0.73	17.84

For the year ended 31st March, 2022**

For the year ended 31st March, 2022**

For the year ended

For the year ended

On adoption of Ind AS 116 Leases, the Company has recognised Right-of-use assets and created lease obligation representing present value of future minimum lease payments.

For the year ended

DETAILS OF DEPRECIATION AND AMORTIZATION AS RESTATED

	518t Waren, 2023	March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021
Depreciation on property plant and equipment	13.95	15.14	7.99	23.13	24.31
Depreciation on Right-of-use assets	1.68	1.03	0.74	1.77	1.76
TOTAL	15.63	16.18	8.72	24.90	26.07

Particulars	For the year ended	For the	year ended 31st March,	2022**	For the year ended
	31st March, 2023	16th August 2021 to March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021
Manufacturing and Operating Costs					
Consumption of stores and spare parts	1.27	0.25	0.36	0.62	1.0
Consumption of Power & Steam	72.60	32.35	10.57	42.93	30.9
Water & Drainage Charges	1.11	0.78	0.06	0.84	0.6
Repairs & Maintenance-					
- Plant & Machinery	12.92	5.54	3,99	9,53	13.3
- Building	3.17	2.55	1.68	4.22	1.8
Insurance Charges	1.47	0.34	1.04	1.39	0.7
Labour Charges	21.80	10.56	4.70	15.26	14.9
Weighing Charges	0.09	0.05	0.02	0.07	0.0
Rent Paid	0.21	=	-	-	_
Analytical Fees	0.23	0.15	0.14	0.29	0.2
Lab Expenses	2.07	0.50	0.28	0.78	0.5
Loading & Unloading charges	0.24	0.22	0.09	0.31	0.2
Safety & Security Charges	0.62	0.34	0.15	0.48	0.4
Professional Fees	4.60	3.43	(0.36)	3.08	4.7
Auditor's Remuneration	0.46	0.30		0.30	-
Effluent Treatment Plant Charge	2.11	1.46	0.57	2.03	1.8
Commission and Incentives on sales	17.93	11.66	1.02	12.68	6.2
Freight Charges	11.18	4.82	2.50	7.32	8,3
Sundry Balance writeoff	2.20	1.67	-	1,67	0.0
Motor Car Expenses	0.50	0.40	0.14	0.54	
CORPORATE Social Responsibility	6.29				
Other Expenses	5.80	1.95	6.94	8,90	2.77
TOTAL	168.87	79.33	33.91	113.24	89.02



For the year ended For the year ended 31st March, 2022** particulars For the year ended 1st April 2021 to 15th 31st March, 2023 16th August 2021 to March 2022 31st March, 2021 For the year ended August 2021 31st March, 2022 for Statutory Audit 0.15 for Other Services - Certification 0.30 0.15 0.15 Total payment to auditors

*Note: The following is the break-up of Auditor's remuneration (excluding input credit / GST availed, if any) 0.30 0.30 36 OTHER FINANCIAL INFORMATION AS RESTATED

289.98

350.91

3,25,60,000

For the year ended 31st March, 2022**

1st April 2021 to 15th

August 2021

For the year ended 31st March, 2022**

1st April 2021 to 15th

August 2021

47.54

112.64

2,82,60,000

227.42

310.54

2,88,96,164

16th August 2021 to

March 2022

For the year ended

274.96

423.18

2,88,96,164

31st March, 2022

For the year ended

31st March, 2022

36.1 Reconciliation of restated net worth and return on restated net worth & Reconciliation of net asset value per equity share

purpose) (A)

year)

GST matters Income tax matters Labour laws related matters (ESIC) Others- Bank guarantees

at year end

39 Segment Information

particulars

Restated PAT as per statement of profit & loss (Rs. In lacs) (For Basic EPS

Weighted average number of Equity Shares for Basic Earnings Per Share (nos.) (Previous year numbers include Bonus Shares issued during current

Restated Earnings before Interest, Tax, Depreciation and Amortisation

35.1 Details of payments to Auditors (excluding GST)

For the year ended 31st March, 2023 16th August 2021 to March 2022

Weighted average number of Equity Shares for Diluted Earnings Per Share**	4	1	1			
(nos.) (Previous year numbers include Bonus Shares issued during current	4				1	
year)	3,25,60,000	2,88,96,164	2,82,60,000	2,88,96,164	2,82,60,000	
Basic Earnings Per Share (in Rs)	8.91	7.87	1.68	9.52	10.83	
Diluted Earnings Per Share (in Rs)	8.91	7.87	1.68	9.52	10.8	
Number of Shares for Computation of EPS - Numbers						
Particulars	For the year ended For the year ended 31st March. 2022**				For the year ended	
		16th August 2021 to March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021	
Basic and Diluted EPS (in Nos)						
Existing (Nos)	1,62,80,000	1,05,00,000	1,05,00,000	1,05,00,000	1,05,00,00	
Right issue share	- '	6,36,164		6,36,164	-	
Total Number of shares after conversion	1,62,80,000		1,05,00,000		1,05,00,00	
Bonus Issue in Previous year	-	14,80,000	14,80,000			
			1 4 40 00 000	1 (2 00 000		
Bonus Issue in current year Bonus Issue in current year Total Number of shares after Bonus issue	1,62,80,000	1,62,80,000	1,62,80,000	1,62,80,000		

37 Contingent Liabilities particulars

Total

Claims against the Company not acknowledged as debts

particulars	For the year ended	For the	For the year ended		
	31st March, 2023	16th August 2021 to March 2022	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances) Letters of Credit and Bank guarantees issued by bankers towards procurement of good, services and other statutory bodies and outstanding as	3.94	8.74	-	8.74	-

0.30

For the year ended

31st March, 2023

The operating segments have been reported in a manner consistent with the internal reporting provided to the Board of Directors, who are the Chief Operating Decision Makers (CODM). The board
responsible for allocating resources and assessing the performance of operating segments. Accordingly, the reportable segment is only one segment i.e. pharmacuticals.
(a) -Revenue from Type of Product and Services
There is only one operating segment of the Company which is based on nature of product. Hence the revenue from external customers shown under geographical information is representative of

revenue based on product and services.

(b) -Geographical Information

For the year ended For the year ended 31st March, 2022*

particulars

For the year ended

	515t March, 2023	March 2022 to	1st April 2021 to 15th August 2021	For the year ended 31st March, 2022	31st March, 2021
Segment Revenue - External Turnover					
Within India	3,326.06	2,077.68	820.19	2.897.86	1,817.62
Outside India	13.04	13.77	3.60	17.37	6,07

vvitnin india	3,326.06	2,077.68	820.19	2,897,86	1,817.62
Outside India	13.04	13.77	3.60	17.37	6.07
Total	3,339.10	2,091.44	823.79	2.915.23	1,823.69
Non-Current Assets*					
Within India	307.17	242.82	242.82	242.82	203.85
Outside India				212.02	203.03
Total	307.17	242.82	242.82	242.82	203.85



For the year ended 31st March, 2021

305.93

500.02

2,82,60,000

For the year ended

31st March, 2021

40 Related Party Transactions

Disclosure on Related Party Transactions as required by Ind AS 24 - Related Party Disclosures is given below:

Holding

Name of holding

Relation Holding

Dhanvallabh Ventures LLP Valiant Organics Limited

Ultimate holding Subsidiary company

Valiant Advanced Sciences Private

Subsidiaries (where control exists):

	Name of the entity	Country of Incorporation	% of Holding as at 31-03-2023	% of Holding as at 31-03-2022	% of Holding as at 31-03-2021
(i)	Valiant Advanced Sciences Private limited	India	100.00%	0.00%	0.00%

(a) Key Managerial Personnel:

Name	Designation
Mr Santosh Vora	Managing Director
Mr Shantilal Vora	Non Executive Director
Mr Paresh Shah	Executive Director & Chief Financial Officer
Mrs. Sonal Vira	Independent Director
Mr Velji K Gogri	Independent Director
Mr Sandeep Gupta - effective from 23rd Feb, 2023	Non Executive Director
Ms Saloni Mehta	Company Secretary

(b) Other entities where significant influence exist:

(i) Post employment-benefit plan entity:
The Trustee Valiant Laboratories Limited Employee Group Gratuity Fund

Compensation of key management personnel of the Company: (Rs In Mn.) March 31, 2023 March 31, March 31, 2021 2022 Short-term employee benefits
 Post-employment benefits# 5.96 1.23 1.38

(iii) Director Sitting fees 0.03 Total compensation paid to key management personnel 6.12 1.41

Name of related party	Nature of transaction	March 3	31, 2023	March 3	31, 2022	March	31, 2021
		Transaction value	Outstanding amount	Transaction value	Outstanding amount	Transaction value	Outstanding amount
Dhanvallabh Ventures LLP	Investment (Share Capital)	-	-	101.75	-		
	Investment Unsec Loan)	-	486.16	589.22	486.16		
	Partner Capital					20.00	577.26
	Rent Received			3.54	-	21.24	1.77
Aarti Industries Limited	Sale of Goods			5.31		13.00	
	Purchase of Goods			5.11		16.91	0.77
	Deposit					-	9.61
	Others - Reimbursement			9.07		27.86	
*	Rent Received	21.24	6.32	17.70			
	Sale of Goods	2.44	-				
Aarti Pharmalabs Limited	Purchase of Goods	41.95	-	20.83	1.59		
	Deposit	-	9.61		9.61		
	Others - Reimbursement	39.45	-	18.18			
Valiant organics limited	Purchase of Goods	2,264.69	460.49	917.55	444.60	29.38	21.88
Valiant Advanced Sciences Private limited	Investment (Share Capital)	0.10	-			-	21.00
	Investment Unsec Loan)	323.33	323.33				

Details of transactions with and balances outstanding of Key Managerial Personnel (KMP) / Close Family Memberof Key Managerial Personnel

	Nature of transaction	March:	31, 2023	March 3	31, 2022	March	31, 2021
		Transaction value	Outstanding amount	Transaction value	Outstanding amount	Transaction value	Outstanding amount
Mr Santosh Vora	Remuneration	1.20	0.10	0.57		0.57	
	Commission to Director	1.43	1.43			0.07	
	Unsecured Loan	-	36.00	102.87	36.00		
	Commission to Director	1.43	1.43		-	-	
Mr Shantilal yora	Sitting Fees	0.05	0.00	0.01	0.01	-	
The state of the s	Remuneration	-	-	0.66	- 0.01	0.66	-
	Unsecured Loan	-	35.89	102.87	35.89		
Mr Paresh Shah	Remuneration	1.50	0.13	0.66	-	0.66	
	Commission to Director	1.43	1.43			0.00	
*	Unsecured Loan	-	35.94	102.86	35.94	-	
Mrs. Sonal Vira	Sitting Fees	0.05	0.01	0.01	0.01	-	
Mr Velji K Gogri	Sitting Fees	0.05	0.01	0.01	0.01		
Ms Saloni Mehta	Salary	0.40	0.04	0.15	0.01		

Details of transactions with and balances outstanding of Entities Controlled/Significantly influenced by Directors/Close Family Members of Directors

Name of related party Nature of transaction	March	31, 2023	March:	31, 2022	March	31, 2021
	Transaction value	Balance as on 31.03.2023	Transaction value	Balance as on 31.03.2022	Transaction value	Balance as on 31.03.2021
The Trustee Valiant Laboratories Limited Contribution to the Gratuity Funds Employee Group Gratuity Fund	0.19	8.64	1.95	9.20	1.53	7.67



1.23

41 Financial Instruments - Accounting Classification and Fair values
Disclosure pursuant to Ind AS 107 "Financial Instruments: Disclosures"

	Current/ Non-		As at 31st March'2023	farch'2023			As at 31st March'2022	farch'2022			As at 31st March'2021	March'2021	(and in out)
	Current	Carrying Amount		Fair Value		Carrying Amount		Fair Value		Carreino	TOTO ME CAT	Dais Walne	
			Level 1	Level 2	Level 3		I posel 1	I avel ?	Land	Amount	V	THE VALUE	
Financial Assets								7 IAAAT	Clavar	THE OWNER OF THE OWNER OWNER OF THE OWNER O	Level 1	Level 2	Level 3
Financial assets measured at cost													
Investment in Subsidiaries	Non-Current	0.10	AN	A	VIV								
Financial assets measured at amortised cost				UW	N.A		N.A	N.A	N.A	1	N.A	N.A	N.A
Security Deposits	Non-Current	2 02	N A	VIV	V 14	9							
Trade Receivables	Current	89 588	V.V	K . Z	A.Y.	01.9	A.Y.	N.A	N.A	5.96	N.A	N.A	A.Z
Balance with Banks	Current	3.21	V.V.	4.7	N.A.	1,107.69	N.A	N.A	A.N.	424.97	A.N.	N.A	A.Z.
Cash on hand	Curron	3.21	A.V.	A.Y.	Y.A	0.11	A.N.	N.A	N.A	69.0	N.A	A.Z.	N. Z.
Other Fixed Deposits	Current	0.00	A.Y	A.Y.	A.Z.	1.20	A.N	N.A	N.A	38.69	N.A	Y.Z	Z
Loans to employees	Current	0.80	N.A	N.A	A.A	200.00	N.A	N.A	N.A	150.00	N.A.	NA	V
Other Receivables	Current	0.70	A.N.	N.A	N.A	0.01	A.N	N.A	N.A	0.21	A Z	N N	AN
	Current	7.22	N.A	N.A	N.A	7.30	N.A	N.A	N.A	80.48	A	N. N.	V.V.
		905.30				1.322.42				200 00	TANK.	V.V.	C.V.
Financial assets measured at fair value through other										700.59			
comprehensive income (FVTOCI)													
Investments in Equity Shares	Non-Current												
Investments in Equity Shares	Current	340.19	340.19			- 7		•	1	t	۲	•	
		340.19	340.19			400	4.02		1	1	,	,	
Fotal Financial Assets		1 245 48	01.010			70%	4.02						
Financial Liabilities		OE-CE-de	CT*ORC		1	1,326.44	4.02		•	700.99			
Financial liabilities measured at amortised cost													
Long term borrowings - Term Loans from Banks	Non-Current		NA	V	N. A.		:						
Unsecured Loans	Non-Current	294 00	AN	V N	Z. Z.		Y.Y	Y.Y	N.A	2.74	A.N	N.A	A.N.
Long-term maturities of lease obligations	Non-Current	6.13	N. A.	V.V.	Y.Y.	00.440	A.Z.	N.A	N.A		N.A	N.A	A.Z.
Short term borrowings - Working capital loans from Banks	Curront	74.0	N.A.	V.V.	Y.Y.	2.67	N.A	A.A	N.A	0.58	N.A	N.A	A.Z.
Trade Payables	Current		K. N. N.	A.Y.	Y.Z.	12.81	N.A	N.A	N.A	0.77	A.N.	N.A	Y Z
- Due to Micro, Small and Medium Entermises		20.0	N.N.	N.A.	A.Z								
- Due to Others	Current	00.00	A.V.	A.A	Y.Z.	0.18	N.A	N.A	N.A	×	N.A	Z	A.N.
Creditors for Capital Goods	Current	47.50	N.A	A.Y.	A.Z	464.19	N.A	N.A	N.A	122.92	A.Z.	N.A.	AN
Current maturities of finance leases obligations	Current	4.52	N.A	A.N.	A.Z	6.94	N.A	N.A	N.A	1.46	AN	N N	A N
Other Current Liabilities	Current	1.75	A.Z.	A.N.	N.A	1.78	N.A	N.A	N.A	1.95	A Z	Y Z	AN
Total Emancial Lishilitian	Current	99.61	N.A	N.A	N.A	6.13	N.A	N.A	N.A	717	AN	N N	VV
TOWN I THREE THE PROPERTY OF		1.095.33				OT 000 F					X 11.5.	Civi	U.V.

Level 1: Hierarchy includes financial instruments measured using quoted prices. This includes listed equity instruments

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are

This section explains the judgments and estimates made indetermining the fair values of the financial instruments that are (a) recognised and measured at fair value and (b) measured at amortised cost and for which fair values are disclosed in the financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the group has classified its financial instruments into the three levels prescribed under the accounting standard. An explanation of each level followed is given in the table above. Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities etc. included in level 3.



Financial risk management objectives and policies

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's Risk Management framework. The Board has established the Risk Management Committee, which is responsible for developing and monitoring the Company's Risk Management policies. The Committee reports regularly to the Board of Directors on its activities.

The Company's financial assets comprise mainly of investments, cash and cash equivalents, other balances with banks, trade receivables and other receivables and financial liabilities comprise mainly of borrowings, trade payables and other payables.

The Company's activities expose it to market risk, liquidity risk and credit risk. The Company's overall risk management focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the Company. The Company uses derivative financial instruments, such as cross currency swaps and interest rate swaps to hedge foreign currency risk and interest rate risk exposure. Derivatives are used exclusively for hedging purposes and not as trading or speculative instruments.

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risks: interest rate risk, currency risk and other price risk. Financial instruments affected by market risk include borrowings, investments, trade payables, trade receivables and derivative financial instruments.

(i) Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of the financial instruments will fluctuate due to changes in market interest rates. Company's interest rate risk arises from borrowings.

The following table demonstrates the sensitivity on the Company's profit before tax, to a reasonably possible change in interest rates of variable rate borrowings on that portion of loans and borrowings affected, with all other variables held constant:

Interest Rate Sensitivity

A change of 50 bps in interest rates would have following impact on Profit before Tax	March 31, 2023	March 31, 2022	March 31, 2021
Outstanding Borrowing Amount - Variable	-	12.81	0.77
50 BPS increase would (decrease) the Profit before Tax by	-	0.06	0.00
50 BPS decrease would increase the Profit before Tax by	-	(0.06)	(0.00)

(ii) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company transacts in several currencies and consequently the Company is exposed to foreign exchange risk through its sales outside India, and purchases from overseas suppliers in various foreign currencies. The company also has borrowings in foregin currency. The exchange rate between the Indian rupee and foreign currencies has changed substantially in recent years and may fluctuate substantially in the future. Consequently, the results of the Company's operations are affected as the rupee appreciates / depreciates against these currencies. Foreign currency exchange rate exposure is partly balanced by purchase of raw materials and services in the respective currencies.

As at the end of the reporting period, the carrying amounts of the material foreign cu	As at Ma		As at Ma	arch 2022	As at Mare	h 2021
	Amount in foreign currency - USD	Amount in Rupees- INR	Amount in foreign currency - USD	Amount in Rupees- INR	Amount in foreign currency - USD	Amount in Rupees- INR
Liabilities						
Inited States Dollar (USD)	-	-		-	-	-
		-		-	-	
Assets						
United States Dollar (USD)	0.48	39.07	0.85	64.66	1.04	76.44
	0.48	39.07	0.85	64.66	1.04	76.44
Net foreign currency denominated monetory liability/(asset)						
United States Dollar (USD)	0.48	39.07	0.85	64.66	1.04	76.44
Foreign exchange derivatives						
USD (Hedged) - Currency swaps against foreign currency	-	-	-	-	-	-
Net foreign currency denominated monetory liability/(asset) (unhedged)						
United States Dollar (USD)	0.48	39.07	0.85	64.66	1.04	76.44

Foreign Currency Risk Sensitivity

The following tables demonstrate foreign currency sensitivity on unhedged exposure (1% increase /

ion exchange rates will have the following impact on profit before tay)

	FY 202	2-23	FY 20	21-22	FY 2020	-21
	+ 100 BPS	- 100 BPS	+ 100 BPS	- 100 BPS	+ 100 BPS	- 100 BPS
United States Dollar (USD)	0.39	(0.39)	0.65	(0.65)	0.76	(0.76)

(iii) Equity Price Risk

The Company's investments in listed equity securities are susceptible to market price risk arising from uncertainties about future values of the investment securities. The Company's Board of Directors reviews and approves all equity investment decisions.

The following table summarises the sensitivity to change in the price of equity securities held by the Company on the Company's Equity and OCI. These changes would not have an effect on profit or loss.

Particulars	Impact on other	Impact on other components of	Impact on other
	components of		components of
	As at 31st March 2023	As at 31st March 2022	As at 31st March 2021
5% increase	17.01	0.20	-
5% decrease	17.01	0.20	_



Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities, primarily for trade receivables and deposits with banks and other financial assets. The Company ensures that sales of products are made to customers with appropriate creditworthiness. Outstanding customer receivables are regularly monitored by the management. An impairment analysis is performed at each reporting date on an individual basis for major customers. Credit risk on cash and cash equivalents is limited as the Company generally invest in deposits with banks.

Refer footnotes (d) and (e) below note no. 7 for ageing of trade receivables and movement in credit loss allowance.

C. Liquidity Risk

Liquidity risk is the risk that the Company may not be able to meet its financial obligations without incurring unacceptable losses. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company has obtained fund and non-fund based working capital lines from various banks. Furthermore, the Company have access to undrawn lines of committed borrowing/facilities. The Company invests its surplus funds in bank fixed deposits and in mutual funds, which carry no or low market risk. The company consistently generates sufficient cash flows from operations or from cash and cash equivalents to meet its financial obligations including lease liabilities as and when they fall due.

(i) Financing arrangements

	March 31, 2023	March 31, 2022	March 31, 2021
Secured borrowing facilities - Amount used		12.81	3.51
- Amount unused	520.00	180.44	197.00
Total	520.00	193.25	200.51

Maturity profile of financial liabilities

Particulars		March 31, 2023			March 31, 2022			March 31, 2021	
	Less than 1 year	Between 1 to 5 years	Over 5 years	Less than 1 year	Between 1 to 5 years	Over 5 years	Less than 1 year	Between 1 to 5 years	Over 5 years
As on 31st March, 2022									
Borrowings		594.00	-	12.81	594.00	-	0.77	2,74	-
Lease Liabilities	1.75	6.42	-	1.78	2.67	-	1.95	0.58	-
Trade Payables	472.96	-	-	397.24	-	-	122.92		-
Other Financial Liabilities	20.18	-	-	7.69	-	-	8.62	-	-
	494.90	600,43		419.52	596.67	1	134.27	3.33	-

Capital Management

For the purpose of the Company's capital management, capital includes issued equity capital, and all other equity reserves attributable to the equity shareholders. The primary objective of the Company's capital management is to maximise the shareholder value, safeguard business continuity and support the growth of the Company. The Company manages its capital structure and makes suitable adjustments in light of changes in economic conditions.

The Company monitors capital using a gearing ratio, which is net debt divided by total capital. The Company includes within net debt outstanding liabilities towards Borrowings, obligations towards lease less

cash and cash equivalents, other unrestricted balances with banks and current investments.

Particulars	March 31, 2023	March 31, 2022	March 31, 2021
Borrowings - Current and Non-Current	594.00	606.81	3.51
Long-term maturities of Lease obligations	6.42	2.67	0.58
Current maturities of Lease obligations	1.75	1.78	1.95
Less: cash and cash equivalent	(3.76)	(1.31)	(39.37)
Less: other balances with banks	(0.80)	(200.00)	(150.00)
Less: current investments	(340.19)	(4.02)	-
Net Debts	257.43	405.93	(183.33)
Total Equity	1,004.90	714.60	885.82
% Net debt to equity ratio	25.62%	56.81%	-20.70%



Sr. No.	Ratio	Numerator	Denominator	As at 31st March 2023	As at 31st March 2022	As at 31st March 2021
1	Current ratio	Current Assets	Current Liabilities = Total current liabilities - Current maturities of non- current borrowings and lease obligations	3.61	3.18	5.47
2	Net Debt- Equity ratio	Net debt = Non-current borrowings + Current borrowings + Non-current and current lease liabilities - Current investments - Cash and cash equivalents - Other balances with banks (including non-current earmarked balances)	[[Equity = Equity share capital + Other t equity] t	0.30	0.51	(0.29
3	Debt Service Coverage ratio	before tax + Non-cash operating	Repayments of long term borrowings (excluding prepayments)	0.66	0.74	97.39
4	Return on Equity ratio	Profit after tax	Average total equity [Equity = Equity share capital + Other equity]	33.73%	34.36%	48.10%
5	Inventory Turnover ratio	Cost of goods sold	Average Inventory	19.21	21.43	24.29
6	Trade Receivable Turnover ratio	Revenue from Sale of Products and Services	Average Trade Receivable	3.35	3.80	5.65
7	Trade Payable Turnover ratio	Total Purchase (Raw Material + packing Material)	Average Trade Payables	5.85	8.32	16.19
8	Net Capital Turnover ratio	Revenue from Operations	Average Working capital = Current assets - Current liabilities	2.80	3.29	3.97
9	Net Profit ratio	Profit after tax	Revenue from operations	8.68%	9.43%	16.78%
10	Return on Capital Employed	Earnings before interest and tax	Average Capital Employed [Capital Employed = Total Equity + Total Debt]	22.76%	35.75%	70.86%

 $Note: - Company \ is \ converted \ into \ Ltd \ Company \ from \ Partnership \ Firm \ on \ 16-08-2021 \ due \ to \ which \ Variance \ is \ not \ acertainable \ .$

